WO2004080998A1 - Imidazol-4-yl-ethynyl-pyridine derivatives - Google Patents

Imidazol-4-yl-ethynyl-pyridine derivatives Download PDF

Info

Publication number
WO2004080998A1
WO2004080998A1 PCT/EP2004/002276 EP2004002276W WO2004080998A1 WO 2004080998 A1 WO2004080998 A1 WO 2004080998A1 EP 2004002276 W EP2004002276 W EP 2004002276W WO 2004080998 A1 WO2004080998 A1 WO 2004080998A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
imidazol
ylethynyl
halogen
compound
Prior art date
Application number
PCT/EP2004/002276
Other languages
French (fr)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Sabine Kolczewski
Richard Hugh Philip Porter
Eric Vieira
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ541643A priority Critical patent/NZ541643A/en
Priority to AU2004220382A priority patent/AU2004220382B2/en
Priority to JP2006504558A priority patent/JP4404896B2/en
Priority to DE602004013746T priority patent/DE602004013746D1/en
Priority to BRPI0408093-9A priority patent/BRPI0408093A/en
Priority to ES04717578T priority patent/ES2305739T3/en
Priority to PL04717578T priority patent/PL1606277T3/en
Priority to SI200430735T priority patent/SI1606277T1/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to DK04717578T priority patent/DK1606277T3/en
Priority to EP04717578A priority patent/EP1606277B8/en
Priority to CA002516682A priority patent/CA2516682C/en
Priority to MXPA05009524A priority patent/MXPA05009524A/en
Publication of WO2004080998A1 publication Critical patent/WO2004080998A1/en
Priority to IL170129A priority patent/IL170129A/en
Priority to HR20050774A priority patent/HRP20050774A2/en
Priority to NO20054136A priority patent/NO20054136L/en
Priority to HK06109889A priority patent/HK1089443A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present invention relates to novel imidazole derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
  • the present invention provides in a first aspect novel 4- [1 -aryl and 1- heteroaryl-imidazol-4-ylethynyl] -2-alkyl-pyridine derivatives as well as pharmaceutically acceptable salts thereof.
  • R 1 is Q- alkyl
  • R 2 is Ci-C 6 alkyl or C 3 ⁇ C 12 cycloalkyl
  • R 3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, C alkyl, S-CrC ⁇ alkyl, - alkyl-halogen, C ⁇ -C 6 alkoxy, halogen-Ci-C 6 alkoxy, C 3 -C ⁇ 2 cycloalkyl, C 2 - C ⁇ heterocycloalkyl, CrC ⁇ alkylamino, di-Ci-C ⁇ alkylamino, -Cealkoxyamino, ( -
  • R 4 is hydrogen, C(O)H or CH 2 R 5 wherein R 5 is hydrogen, OH, CrC 6 alkyl or C 3 -
  • the present invention provides a compound of formula I* wherein
  • R 1 signifies lower alkyl
  • R 2 signifies lower alkyl
  • R 3 signifies aryl or heteroaryl, optionally substituted, preferably by one, two or three substituents, selected from the group consisting of halogen, lower alkyl, lower alkyl- halogen or cyano; as well as to pharmaceutically acceptable salts thereof.
  • the compounds of general formula I are metabo- tropic glutamate receptor 5 antagonists.
  • Compounds of formula I are distinguished by having valuable therapeutic properties. They can be used in the treatment or prevention of mGluR5 receptor mediated disorders.
  • the transmission of stimuli takes place by the interaction of a neurotransmitter, which is sent out by a neuron, with a neuroreceptor.
  • Glutamate is the major excitatory neurotransmitter in the brain and plays a unique role in a variety of central nervous system (CNS) functions.
  • the glutamate-dependent stimulus receptors are divided into two main groups.
  • the first main group namely the ionotropic receptors, forms ligand-controlled ion channels.
  • the metabotropic glutamate receptors (mGluR) belong to the second main group and, furthermore, belong to the family of G- protein coupled receptors.
  • these eight receptors can be sub-divided into three sub-groups:
  • mGluRl and mGluR5 belong to group I
  • mGluR2 and mGluR3 belong to group II
  • mGluR4 mGluR6, mGluR7 and mGluRS belong to group III.
  • Ligands of metabotropic glutamate receptors belonging to the first group can be used for the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits, as well as chronic and acute pain.
  • acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits, as well as chronic and acute pain.
  • treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia.
  • Further treatable indications are ischemia, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopafhic parkinsonism or parkin- sonism caused by medicaments as well as conditions which lead to glutamate- deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, drug abuse/dependance such as nicotine addiction, opiate addiction, and alcohol abuse, anxiety, vomiting, dyskinesia and depressions.
  • ALS amyotrophic lateral sclerosis
  • dementia caused by AIDS
  • eye injuries retinopathy
  • idiopafhic parkinsonism or parkin- sonism caused by medicaments as well as conditions which lead to glutamate-
  • Disorders mediated full or in part by mGluR5 are for example acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain and drug dependency [Expert Opin. Ther. Patents 12:12 (2002)].
  • Selective mGluR5 antagonists are especially useful for the treatment of anxiety and pain.
  • Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts, the above-mentioned compounds as pharmaceutically active substances and their production. Further objects of the invention are medicaments based on a compound in accordance with the invention and their manufacture as well as the use of the compounds in the control or prevention of mGluR5 receptor mediated disorders, and, respectively, for the production of corresponding medicaments.
  • lower alkyl used in the present description denotes straight-chain or branched saturated hydrocarbon residues with 1 to 6 carbon atoms, preferably with 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl and the like.
  • the term “diagoalkyl” used in the present description denotes cyclic saturated hydrocarbon residues with 3 to 12 carbon atoms. Examples for cycloallcyl include cyclopropyl, cyclobutyl and cyclopentyl.
  • Examples for -Csalko y include mefhoxy, methoxyethyl and methoxyethoxy.
  • Examples for halogenmethoxy include trifluoromethoxy.
  • Examples for C 2 -C ⁇ heterocycloaIkyl include pyrrolidinyl, morpholinyl and thiomorpho- linyl.
  • Examples for -Csalkylamino include methylamino and ethylamino.
  • Examples for di- - C 6 al_kylamino include dimethylamino.
  • Examples for -Cealkoxyamino include methoxy- ethylamino.
  • Examples for (C 1 -C 6 alkoxy)C 1 -C 6 aIkylamino include (methoxyethyl)methyl- amino.
  • Examples for methoxycycloalkylamino include cyclopropylamino.
  • halogen denotes fluorine, chlorine, bromine and iodine.
  • Aryl represents an aromatic carbocyclic group consisting of one individual ring, or one or more fused rings in which at least one ring is aromatic in nature. Examples for aryl in- elude phenyl. Examples for substituted aryl include fluorophenyl, difluorophenyl, chloro- phenyl, dichlorophenyl, chlorofluorophenyl, cyanophenyl, methylphenyl, methoxyphenyl, fluoromethylphenyl, trifluoromethylphenyl and trifluoromethoxyphenyl.
  • heteroaryl refers to an aromatic 5- or 6-membered ring or one or more fused rings containing one or more heteroatoms selected from nitrogen, oxygen or sulphur.
  • heteroaryl groups are pyrimidinyl, pyrazinyl, pyridazinyl, pyridinyl and indolyl, e.g. pyridin-4-yl, pyridin-2-yl, pyrazin-2-yl and pyrimidin-2-yl.
  • substituted heteroaryl examples include methylpyrimidinyl, dimethylpyrimidinyl, trifluoromethylpyri- midinyl, mefhoxypyrimidinyl, methoxyethoxypyrimidinyl, ethylpyrimidinyl, fluoropyri- midinyl, chloropyrimidinyl, bromopyrimidinyl, methylsulfanylpyrimidinyl, cyclopropyl- pyrimidinyl, methylpyrazinyl, cyclopropylpyrazinyl, chloropyrazinyl, methoxypyrazinyl, methoxyethoxypyrazinyl, methylaminopyrazinyl, dimethylaminopyrazinyl, cyclopropyl- aminopyrazinyl, morpholinylpyrazinyl, fluoropyridinyl, chloropyridinyl, bromopyridinyl, iodopyridin
  • pharmaceutically acceptable salt refers to any salt derived from an inorganic or organic acid.
  • “Pharmaceutically acceptable salts” of a compound means salts that are pharmaceutically acceptable, which are generally safe, non-toxic, and neither biologically nor otherwise undesirable, and that possess the desired pharmacological activity of the parent compound. These salts are derived from an inorganic or organic acid. If possible, compounds of formula I may be converted into pharmaceutically acceptable salts.
  • references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) of the same acid addition salt.
  • Examples for pharmaceutically acceptable acid addition salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucohep tonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaph- thoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, dibenzoyl-L-tartaric acid, tartaric acid, p-toluene-sulfonic acid, trimethylacetic acid, trifluoro
  • Preferred compounds of formula I* are those, in which R 1 and R 2 are both methyl.
  • R 3 is substituted phenyl, wherein the substitution is fluoro, chloro, cyano or CF 3 .
  • Examples of compounds, wherein the substitution is cyano are as follows: 4- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -benzonitrile, or 3-[2-methyl-4-(2-mefhyl-pyridin-4-ylethynyl)-imidazol-l-yl]-benzonitrile.
  • R 1 and R 2 are both methyl and R 3 is pyrimidinyl, for example the following compound: 2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyrimidine.
  • the present invention provides a compound of formula I wherein R 1 is methyl, and R 2 , R 3 and R 4 independently are as defined above or hereinafter.
  • the present invention provides a compound of formula I wherein R 2 is Ci-Cgalkyl. In another embodiment the present invention provides a compound of formula I wherein R 2 is methyl or isopropyl. In another embodiment the present invention provides a compound of formula I wherein R 2 is cyclopropyl. In all the above embodiments R , R 3 and R 4 independently are as defined above or hereinafter.
  • the present invention provides a compound of formula I wherein R 3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halo- gen, C C ⁇ alkyl, S-Ci-Cgalkyl, Ci-C 6 aIkyl-halogen, C ⁇ -C 6 alkoxy, halogen-Ci-Cealkoxy, C 3 - C 12 cycloalkyl, C 2 -Cnheterocycloalkyl, CrCgalkylamino, di- -C ⁇ alkylamino, CrCgalkoxy- amino, (C 1 -C6alkoxy)C 1 -C 6 alkylamino, C 3 -C ⁇ 2 cycloaIkylamino, benzylamino and cyano.
  • R 3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halo- gen, C C ⁇ alkyl
  • the present invention provides a compound of formula I wherein R 3 is phenyl or phenyl substituted by one, two or three substituents selected from halogen, Ci-Cgalkyl, S- -Cgalkyl, Ci-Cgalkyl-halogen, Ci-C 6 alkoxy, halogen- -Cgalkoxy, C 3 -
  • the present invention provides a compound of formula I wherein R 3 is phenyl or phenyl substituted by one or two substituents selected from halogen, C Cgalkyl, CrCgalkyl-halogen, -Cgalkoxy, halogen- -Cgalkoxy and cyano.
  • the present invention provides a compound of formula I wherein R 3 is phenyl substituted by one or two substituents selected from halogen, -Cgalkyl, - C 6 alkyl-halogen, Ci-Cgalkoxy, halogen-Ci-C 6 aIkoxy and cyano.
  • R 3 is phenyl substituted by one or two substituents selected from fluoro, chloro, methyl, trifluoromethyl, methoxy, trifluoromethoxy and cyano.
  • the present invention provides a compound of formula I wherein R 3 is fluorophenyl, difluorophenyl, chlorophenyl, di- chlorophenyl, cyanophenyl, trifluoromethylphenyl, fluoro-methylphenyl, chloro-fluoro- phenyl, methylphenyl, methoxyphenyl or trifluoromethoxyphenyl.
  • R 3 is fluorophenyl, difluorophenyl, chlorophenyl, di- chlorophenyl, cyanophenyl, trifluoromethylphenyl, fluoro-methylphenyl, chloro-fluoro- phenyl, methylphenyl, methoxyphenyl or trifluoromethoxyphenyl.
  • the present invention provides a compound of formula I wherein R 3 is unsubstituted heteroaryl or heteroaryl substituted by one, two or three substituents selected from the group consisting of halogen, Ci-Cgalkyl, S-Ci-Cgalkyl, -Cgalkyl-halo- gen, Ci-Cgalkoxy, halogen-CrCgalkoxy, C 3 -C ⁇ 2 cycloaIkyl, C 2 -C ⁇ heterocycloalkyl, Q- Cgalkylamino, di-Ci-Cgalkylamino, Ci-Cgalkoxyamino, (Ci-Cgalkoxy)C ⁇ -C 6 alkylamino, C 3 -Ci 2 cycloalkylamino, benzylamino and cyano.
  • substituents selected from the group consisting of halogen, Ci-Cgalkyl, S-Ci-Cgalkyl, -Cgalkyl-halo- gen, Ci-
  • the present invention provides a compound of formula I wherein R 3 is unsubstituted pyrimidinyl, unsubstituted pyrazinyl or unsubstituted pyridinyl.
  • R 3 is heteroaryl selected from pyrimi- dinyl, pyrazinyl, pyridinyl and indolyl wherein the heteroaryl is substituted by one or two substituents selected from halogen, Ci-Cgalkyl, S-CrCgalkyl, Ci-Cgalkyl-halogen, Q- Cgalkoxy, C 3 -C 12 cycloalkyl, C 2 -Cnheterocycloalkyl, -Cgalkylamino, di- -Cgalkylamino, CrCgalkoxyamino, (Ci-Cgalkoxy)C ⁇ -Cgalkylamino, C 3 -C ⁇ 2 cycloalkylamino and
  • the present invention provides a compound of formula I wherein R 3 is pyrimidinyl substituted by one or two substituents selected from halogen, Ci-Cgalkyl, S-Ci-C ⁇ alkyl, Ci-Cgalkyl-halogen, -Cgalkoxy and C 3 -C ⁇ 2 cycloalkyl; or pyrazinyl substituted by one substituent selected from halogen, Ci-Cgalkyl, Ci-Cgalkoxy, C 3 -C 12 cycloalkyl, C 2 -C ⁇ heterocycloalkyl, Ci-Cgalkylamino, di-Ci-Cgalkylamino and C 3 - C 12 cycloalkylamino; or pyridinyl substituted by one or two substituents selected from halogen, d-Cgalkyl, CrCgalkyl-halogen, Q-Cgalkoxy, C 3 -C 12 cycloalkyl, C 2 -C ⁇ hetero-
  • the present invention provides a compound of formula I wherein R 3 is methylpyrimidinyl, ethylpyrimidinyl, dimethylpyrimidinyl, trifluoromethylpyrimidinyl, methoxypyrimidinyl, methoxyethoxypyrimidinyl, fluoropyrimidinyl, chloropyrimidinyl, bromopyrimidinyl, methylsulfanylpyrimidinyl, cyclopropylpyrimidinyl, methylpyrazinyl, cyclopropylpyr- azinyl, mefhoxypyrazinyl, chloropyrazinyl, methylaminopyrazinyl, dimethylaminopyr- azinyl, cyclopropylpyrazinyl, mefhylpyridinyl, butylpyridinyl, fluoropyridinyl, chloro- pyridinyl, bromopyridinyl, io
  • the present invention provides a compound of formula I wherein R 4 is hydrogen, C(O)H or CH 3 . In another embodiment the present invention provides a compound of formula I wherein R 4 is hydrogen. In all the above embodiments R 1 , R 2 and R 3 independently are as defined above or hereinafter.
  • the present invention provides a compound of formula I wherein R 1 is methyl
  • R 2 is Ci-Cgalkyl or C 3 -C 12 cycloalkyl
  • R 3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, CrCgalkyl, S-CrCgalkyl, - Cgalkyl-halogen, CrCgalkoxy, halogen-CrCgalkoxy, C 3 -C 12 cycloalkyl, C 2 -
  • R 4 is hydrogen, C(O)H or CH 2 R 5 wherein R 5 is hydrogen, OH, CrCgalkyl or C 3 -
  • the present invention provides a compound of formula I wherein R 1 is methyl
  • R 2 is methyl, isopropyl or cyclopropyl
  • R 3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, CrCgalkyl, S-Ci-Cgalkyl, - Cgalkyl-halogen, CrCgalkoxy, halogen-CrCgalkoxy, C 3 -C 12 cycloalkyl, C 2 -
  • R 4 is hydrogen, C(O)H or CH 2 R 5 wherein R 5 is hydrogen, OH, CrCgalkyl or C 3 -
  • R 1 is methyl
  • R 2 is methyl, isopropyl or cyclopropyl
  • R 3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, CrCgalkyl, S-CrCgalkyl, Ci-
  • Cgalkyl-halogen Ci-Cgalkoxy, halogen-CrCgalkoxy, C 3 -C ⁇ 2 cycloalkyl, C 2 - C ⁇ heterocycloalkyl, CrCgalkylamino, di-Ci-Cgalkylamino, CrCgalkoxyamino, (Ci- Cgalkoxy) CrCgalkylamino, C 3 -Ci 2 cycloal_kylamino, benzylamino and cyano; and
  • R 4 is hydrogen, C(O)H or methyl.
  • R 1 is methyl
  • R 2 is methyl, isopropyl or cyclopropyl
  • R 3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, Ci-Cgalkyl, S-Ci-Cgalkyl, Q- C 6 alkyl-halogen, Ci-Cgalkoxy, halogen-Ci-Cgalkoxy, C 3 -C ⁇ 2 cycloalkyl, C 2 - Ciiheterocycloalkyl, CrCgalkylamino, di-Ci-Cgalkylamino, Ci-Cgalkoxyamino, (Q- Cgalkoxy)C ⁇ -Cgalkylamino, Q-Cncydoalkylamino, benzylamino and cyano; and R is hydrogen.
  • R and R are methyl
  • R 3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, Ci-Cgalkyl, S-CrCgalkyl, Q- Cgalkyl-halogen, Q-Cgalkoxy, halogen-Q-Cgalkoxy, C 3 -C 12 cycloalkyl, C 2 -
  • R 1 and R 2 are methyl
  • R 3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halogen, Q-Cgalkyl, S-CrCgalkyl, Q-Cgalkyl-halogen, Ci-Cgalkoxy, halogen-Q- Cgalkoxy, Q-Cncycloalkyl, C 2 -Qiheterocycloalkyl, Ci-Cgalkylamino, di-Q-Cgalkyl- amino, CrCgalkoxyamino, (CrCgalkoxy)Q-Cgalkylamino, C3-C ⁇ 2 cycloalkylamino, benzylamino and cyano; and R 4 is hydrogen.
  • the present invention provides a compound of formula I wherein R 1 and R 2 are methyl;
  • R 3 is phenyl or phenyl substituted by one, two or three substituents selected from halogen, Ci-Cgalkyl, S-Ci-Cgalkyl, Q-Cgalkyl-halogen, Ci-Cgalkoxy, halogen-Ci- Cgalkoxy, C 3 -Q 2 cycloalkyl, -Qiheterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkyl- amino, CrCgalkoxyamino, (Q-Cgalkoxy)Ci-Cgalkylamino, C 3 -C ⁇ 2 cycloalkylamino, benzylamino and cyano; and
  • R 4 is hydrogen
  • R 1 and R 2 are methyl;
  • R 3 is phenyl or phenyl substituted by one or two substituents selected from halogen, Q-
  • R 1 and R 2 are methyl
  • R 3 is phenyl substituted by one or two substituents selected from fluoro, chloro, methyl, trifluoromethyl, methoxy, trifluoromethoxy and cyano; and R 4 is hydrogen.
  • R 1 and R 2 are methyl
  • R 3 is fluorophenyl, difluorophenyl, chlorophenyl, dichlorophenyl, cyanophenyl, tri- fluoromethylphenyl, fluoro-methylphenyl, chloro-fluorophenyl, methylphenyl, mefh- oxyphenyl or trifluoromethoxyphenyl;
  • R 4 is hydrogen
  • R 1 and R 2 are methyl;
  • R 3 is unsubstituted heteroaryl or heteroaryl substituted by one, two or three substituents selected from the group consisting of halogen, Ci-Cgalkyl, S-Q-Cgalkyl, Ci-Cgalkyl- halogen, CrCgalkoxy, halogen-Ci-Cgalkoxy, Q-Cncycloalkyl, C -Q ⁇ heterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkylamino, Q-Cgalkoxyamino, (Q-CgalkoxyJQ-Cgalkyl- amino, C 3 -Q 2 cycloalkylamino, benzylamino and cyano; and R 4 is hydrogen.
  • R 1 and R 2 are methyl
  • R 3 is unsubstituted pyrimidinyl, unsubstituted pyrazinyl or unsubstituted pyridinyl; and R 4 is hydrogen.
  • R 1 and R 2 are methyl;
  • R 3 is heteroaryl selected from pyrimidinyl, pyrazinyl, pyridinyl and indolyl wherein the heteroaryl is substituted by one or two substituents selected from halogen, Q-Cgalkyl, S-Q-Cgalkyl, Q-Cgalkyl-halogen, Q-Cgalkoxy, C 3 -C ⁇ 2 cycloalkyl, Q-Qiheterocyclo- alkyl, Q-Cgalkylamino, di-Q-Cgalkylamino, Q-Cgalkoxyamino, (Q-Cgalkoxy) Q- Cgalkylamino, C 3 -C ⁇ 2 cycloalkylamino and benzylamino; and
  • R 4 is hydrogen
  • R 1 and R 2 are methyl;
  • R 3 is pyrimidinyl substituted by one or two substituents selected from halogen, Ci- Cgalkyl, S-Q-Cgalkyl, Ci-Cgalkyl-halogen, Q-Cgalkoxy and C 3 -C 12 cycloalkyl; or pyrazinyl substituted by one substituent selected from halogen, Q-Cgalkyl, Ci-Cgalkoxy, C 3 -Q 2 cycloalkyl, C 2 -Q ⁇ heterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkylamino and C 3 -Q 2 cycloalkylarnino; or pyridinyl substituted by one or two substituents selected from halogen, Q-Cgalkyl, Q-Cgalkyl-halogen, Ci-Cgalkoxy, Q-C ⁇ cycloalkyl,
  • R 4 is hydrogen
  • R 1 and R 2 are methyl
  • R 3 is methylpyrimidinyl, ethylpyrimidinyl, dimethylpyrimidinyl, trifluoromethylpyri- midinyl, methoxypyrimidinyl, methoxyethoxypyrimidinyl, fluoropyrimidinyl, chloropyrimidinyl, bromopyrimidinyl, methylsulfanylpyrimidinyl, cyclopropylpyrimidinyl, methylpyrazinyl, cyclopropylpyrazinyl, methoxypyrazinyl, chloropyrazinyl, methyl- aminopyrazinyl, dimethylaminopyrazinyl, cyclopropylpyrazinyl, methylpyridinyl, butylpyridinyl, fluoropyridinyl, chloropyridinyl, bromopyridinyl, iodopyridinyl, tri- fluoromethylpyridinyl, (triflu
  • R 4 is hydrogen
  • Examples of compounds of formula I include 4-[l-(4-fluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, -[l-(3,4-dichloro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine hydro- chloride, -[l-(2,4-difluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl]-2-methyl-pyridine, - [l-(3,4-difluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, -[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-benzonitrile, -[2-methyl-4-(2-methyl-pyridin-4-
  • the present invention also provides a process for the production of a compound of formula I
  • R 1 is Q-Cgalkyl
  • R 2 is Ci-Cgalkyl or C 3 -C 12 cycloaIkyl
  • R 3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halogen, Q-Cgalkyl, S-Q-Cgalkyl, Ci-Cgalkyl-halogen, Q-Cgalkoxy, halogen-Ci- Cgalkoxy, C 3 -Q 2 cycloalkyl, Q-Qiheterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkylamino, CrCgalkoxyamino, (Q-Cgalkoxy)CrCgalkylamino, Q-C ⁇ cycloalkylamino, benzylamino and cyano, unsubstituted heteroaryl or heteroaryl substituted by one, two or three substituents selected from the group consisting of halogen, Q-Cgalkyl, S- Q
  • R 3 -Z (III) wherein R 3 has the meanings as defined above and Z is halogen or B(OH) 2 ; or (b) a compound of formula IV
  • R 1 has the meanings as defined above and X is halogen; or (c) a compound of formula VI
  • R 1 has the meaning as defined above and Y is trimethylsilyl or hydrogen.
  • the reaction as described in (a) maybe carried out in accordance with standard procedures, e.g. by arylation of a compound of formula II using an aromatic boronic acid and a copper catalyst in a solvent like dichloromethane or tetrahydrofurane [see e.g. Colmann et al., Org. Lett. 2:1233 (2000)] or by heating a compound of formula II and a compound of formula III wherein Z is halogen with a base like potassium carbonate or cesium carbonate in a solvent like dimethylformamide, or Pd catalyzed according to Buchwald conditions [see e.g. Example 8; Buchwald et al., Tetrahedron Lett. 40:2657 (1999)] .
  • the reaction as described in (b) may be carried out by a Sonogashira coupling of a compound of formula IV and a compound of formula V in the presence of, e.g., Cul, (Ph 3 P) 2 PdCl , Et ⁇ N in a solvent like tetrahydrofuran or dimethylformamide [Sonogashira et al, Synthesis 777 (1977)].
  • the meaning X in compounds of formula V is bromine or iodine.
  • the reaction as described in (c) above may, e.g. be carried out in the presence of Cul, (Ph. 3 P) 2 PdCl 2 , Et 3 N, n-Bu F in a solvent like tetrahydrofuran or dimethylformamide.
  • the compounds of formula II may be prepared by reacting a compound of formula VIII wherein R 2 and R 4 have the above meanings and hal is halogen, with a compound of formula VII as above.
  • the compounds of formula VIII may be prepared as described e.g. in Cliff and Pyne [Synthesis 681-682 (1994)].
  • the compounds of formula IV maybe prepared by reacting a compound of formula IX
  • R 3 R 4 wherein R 2 , R 3 and R 4 have the meanings as defined above, with dimethyl (l-diazo-2-oxopropyl)phosphonate as described in Ohira [Synth. Comm. 19:561-564 (1989)].
  • R 3 -B(OH) 2 (X) wherein R 3 has the meanings as defined above.
  • the reaction may take place by arylation of a compound of formula VIII using an aromatic boronic acid (compound of formula X) and a copper catalyst in a solvent like dichloromethane or tetrahydrofurane under an oxygen atmosphere [see e.g. Colmann et al., Org.Lett. 2:1233 (2000)].
  • the reaction may take place by a Sonogashira coupling in the presence of eg. Cul, (Ph 3 P) 2 PdCl 2 , EtaN in a solvent like tetrahydrofuran or dimethylformamide [Sonogashira et al., Synthesis 777 (1977)].
  • Compounds of formula XV may be prepared by treating a compound of formula XVI with a reducing agent according to methods known to the skilled artisan.
  • R 3 -NH 2 (XVIII) with e.g. triethyl orthoformate, ethylnitro acetate, glacial acetic acid and iron powder according to methods known to the skilled artisan.
  • the compounds of general formula I* and their pharmaceutically acceptable salts can be manufactured by two general procedures, which procedures are outlined below for compounds wherein R 1 is methyl and R 2 is methyl, but which procedures are applicable for all compounds according to Formula I*.
  • the invention also relates to a process for preparing a compound according to general formula I* following the general procedures as outlined above for compounds of formula I* wherein R 1 is methyl and R 2 is methyl (R 3 and R 1 are designated Ar and Ar', respectively, in Scheme 2).
  • the invention relates also medicaments containing one or more compounds of the present invention and pharmaceutically acceptable excipients for the treatment and. prevention of mGluR5 receptor mediated disorders, such as acute and/ or chronic neurological disorders, in particular anxiety and chronic or acute pain.
  • the invention also relates to the use of a compound in accordance with the present invention as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and prevention of mGluR5 receptor mediated disorders as outlined above.
  • Pharmaceutically acceptable salts of compounds of formula I can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt.
  • Inorganic or organic acids such as, e.g., hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I.
  • Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation of pharmaceutically acceptable salts of acidic compounds.
  • the compounds of formula I and their pharmaceutically acceptable salts are, as already mentioned above, metabotropic glutamate receptor antagonists and can be used for the treatment or prevention of mGluR5 receptor mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
  • Treatable neurological dis- orders are for instance epilepsy, schizophrenia, anxiety, acute, traumatic or chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Huntington's chorea, ALS, multiple sclerosis, dementia caused by AIDS, eye injuries, re- tinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, con- vulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.
  • glutamate-deficient functions such as e.g. muscle spasms, con- vulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.
  • Treatable kinds of pain include inflammatory pain such as arthritis and rheumatoid disease, vasculitis, neuropathic pain such as trigeminal or herpetic neuralgia, diabetic neuropathy pain, causalgia, hyper- algesia, severe chronic pain, post-operative pain and pain associated with various condi- tions like cancer, angina, renal or billiay colic, menstruation, migraine and gout.
  • cDNA encoding human mGlu 5a receptor was transiently trans- fected into EBNA cells using a procedure described by Schlaeger and Christensen [Cyto- technology 15:1-13 (1998)].
  • Cell membrane homogenates were stored at -80°C until the day of assay where upon they were thawed and resuspended and polytronised in 15 mM Tris-HCl, 120 mM NaCl, 100 mM KC1, 25 mM CaCl 2 , 25 mM MgCl 2 binding buffer at pH 7.4 to a final assay concentration of 20 ⁇ g protein/ well.
  • membranes were filtered onto unifilter (96-well white micro- plate with bonded GF/C filter preincubated 1 h in 0.1% PEI in wash buffer, Packard Bio- Science, Meriden, CT) with a Filtermate 96 harvester (Packard BioScience) and washed 3 times with cold 50 mM Tris-HCl, pH 7.4 buffer. Nonspecific binding was measured in the presence of 10 ⁇ M MPEP. The radioactivity on the filter was counted (3 min) on a Packard Top-count microplate scintillation counter with quenching correction after addition of 45 ⁇ l of microscint 40 (Canberra Packard S.A., Zurich, Switzerland) and shaking for 20 min.
  • Ki value is defined by the following formula:
  • Ki IC 50 / [l + L / K d ]
  • IC 50 values are those concentrations of the compounds tested which cause 50 % inhibition of the competing radioligand ([ 3 H]MPEP).
  • L is the concentration of radioligand used in the binding experiment and the Ka value of the radioligand is empiri- cally determined for each batch of membranes prepared.
  • Pharmaceutical Compounds are mGluR 5a receptor antagonists.
  • the activities of Pharmaceutical Compounds as measured in the assay described above are in the range of Kj ⁇ 150 nM.
  • the Vogel conflict drinking test is a procedure that has been widely used as a screening method for anxiolytics.
  • the water intake of thirsty rats is measured under conditions where water intake is suppressed by electric shock.
  • rats are water-restricted for 23h during three consecutive days. One day after the first water restriction, they are allowed to freely drink for one hour in their home-cage. The second day, they are allowed to lick from a drinking spout in the operant box for 15 min, after which they are allowed to freely drink in their home cage for one hour.
  • Pharmaceutical Compounds can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emul- sions or suspensions.
  • the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • Pharmaceutical Compounds can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, e.g., as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like.
  • Adjuvants such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • medicaments containing a Pharmaceutical Compound and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more Pharmaceutical Compound and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described.
  • Step 1 2-Methyl- 1 - (2-trimethylsilanyl-ethoxymethyl) - lH-imidazole-4-carbaldehyde and
  • Step 2 4-Ethynyl-2-methyl-l-(2-frimemylsflanyl-etfroxymethyl)-lH-imidazole and 5- ethynyl-2-methyl-l-(2-trimethylsilanyl-ethoxymefhyl)-lH-imidazole (l-Diazo-2-oxo-propyl)- ⁇ hosphonic acid dimethyl ester (10.4 g, 54 mmol) was dissolved in 150 mL methanol. Potassium carbonate (12.6 g, 90 mmol) was added.
  • Step 4 2-Methyl-4-(2-methyl-lH-imidazol-4-ylethynyl -pyridine 2-Methyl-4-[2-me1 ⁇ yl-l-(2-trimethylsflanyl-ethoxymethyl)-lH-imidazol-4-ylethynyl]- pyridine and 2-methyl-4- [2-methyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazol-4- ylethynyl] -pyridine (2.85 g, 8.7 mmol) were dissolved in 50 mL EtOH saturated with HCl. The reaction mixture was stirred at RT overnight. The solvent was evaporated.
  • Step 1 4-Iodo-2-methyl-pyridine 4-Chloropicoline (10 g, 78 mmol), sodium iodide (17.8 g, 118 mmol) and hydroiodic acid (57%, 26 mL, 196 mmol) were heated in a sealed class tube at 140°C for 7 days. The reaction mixture was poured into ice water and neutralized by addition of sodium hydroxide. This mixture was extracted three times with dichloromethane (300 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The desired product was obtained as an off-white solid (14.7 g, 85%) and used without any further purification for the next step. Sje ⁇ 2-Methyl-4-trimethylsilanylethynyl-pyridine
  • the reaction mixture was stirred at RT overnight. The solvent was evaporated. The residue was taken up in 500 mL water and extracted three times with ethyl acetate (500 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane/ethyl acetate gradient 100:0 — 0:100). The desired product was obtained as a light brown liquid (8.18 g, 99%).
  • Step 3 2-Methyl-4-(2-methyl-lH-imidazol-4-ylethynyl -pyridine Solution 1: 2-Mefhyl-4-trimethylsilanylethynyl-pyridine (12 g, 74 mmol) and 5-iodo-2- methyl- lH-imidazole (13.24 g, 64 mmol, synthesis: Cliff and Pyne, Synthesis 681-682
  • Solution 2 Triphenylphosphine (223 mg, 0.85 mmol), bis (triphenylphosphine) -palladi- um(II) chloride (1.79 g, 2.55 mmol), copper(I)iodide (81 mg, 0.43 mmol) and triethyl amine (8.87 mL, 64 mmol) were dissolved in 75 mL dry THF. This mixture was also evacuated and backfilled with argon several times to remove oxygen from the solution. Solution 2 was heated to 40°C and solution 1 was added dropwise.
  • the reaction mixture was heated to 60°C and tetrabutylammonium fluoride solution (1M in THF, 55 mL, 55 mmol) was added dropwise during 45 min. The reaction was than stirred at RT overnight. The solvent was evaporated. The residue was taken up in 200 mL water and extracted three times with ethyl acetate (200 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by chromatography on silica gel (methylene chloride/methanol 95:5) and recrystallized from a mixture of methylene chloride and ethyl acetate. The desired product was obtained as a light brown solid (7.44 g, 59%).
  • Example III- 1 2-Chloro-5-methyl-pyrazine (III-l) 2-Hydroxy-5-methylpyrazine (0.984g, 8.94 mmol) was refluxed in 15 mL phosphoroxy- chloride for 1.5h. The reaction mixture was slowly poured into ice and adjusted to pH6 by addition of sodium carbonate. The mixture was extracted six times with ethyl acetate (50 mL each). The combined organic extracts were dried with sodium sulfate, filtered and eva- porated. The crude product was used without any further purification for the next step.
  • This compound was prepared according to WO 92/11,241.
  • Example IV- 1 4-Emynyl-l-(4-fluoro-phenyl)-2-methyl-lH-imidazole (IV-1)
  • Step 1 l-(4-Fluoro-phenyl)-lH-imidazole-4-carboxylic acid ethyl ester 4-Fluoroaniline (20.0 g, 175 mmol) was mixted at RT with triethyl orthoformate (35.4 g, 233 mmol), ethylnitro acetate (28.5 g, 210 mmol) and 4 mL glacial acetic acid. The reaction mixture was refluxed with mechanical stirring for 2h. More triethyl orthoformate (200 mL) and glacial acetic acid (200 mL) were added. Iron powder (100 g, 1.79 mol) was added in 3 portions during 8h while maintaining the reaction mixture at reflux.
  • Step 2 l-(4-Fluoro-phenyl)-lH-imidazole-4-carboxylic acid
  • Step 3 [l-(4-Fluoro-phenyl)-lH-imidazol-4-yl]-methanol l-(4-Fluoro-phenyl)-lH-imidazole-4-carboxylic acid (18 g, 87 mmol) was dissolved in 90 mL dry THF. Borane tetrahydrofuran complex (174 mL, 1M in THF, 174 mmol) was added dropwise. The reaction was refluxed for 2h and stirred at RT overnight.
  • Step 6 [l-(4-Fluoro-phenyl)-2-methyl-lH-imidazol-4-yl1 -methanol 4- (tert-Butyl-dimethyl-silanyloxymethyl) - 1- (4-fluoro-phenyl) -2-methyl- lH-imidazole (14.7 g, 45.7 mmol) was dissolved in 200 mL THF. Tetrabutyl ammoniumfluoride (91 mL, IM in THF, 91 mmol) was added and the reaction mixture was stirred at RT overnight. The solvent was evaporated. The residue was taken up in 200 mL water and extracted three times with ethyl acetate (200 mL each).
  • Step 8 4-Ethynyl- 1 - (4-fluoro -phenyl) -2-methyl- lH-imidazole
  • Example 1 4- [ 1 - (4-Fluoro-phenyl) -2-methyl- lH-imidazol-4-ylethynyl] -2-methyl- pyridine (1)
  • Example 2 2- [2-Methyl-4-(2-meth.yl-pyridin-4-ylethynyl)-imidazol- 1-yl] -pyrimidine (8) 2-Methyl-4- (2-methyl- lH-imidazol-4-ylethynyl) -pyridine (II-l) (87 mg, 0.44 mmol) was dissolved in 3 mL dimethyl formamide. Potassium carbonate (122 mg, 0.88 mmol) and 2- chloro-pyrimidine (76 mg, 0.66 mmol) were added and the reaction mixture was refluxed overnight. The reaction mixture was poured into 60 mL water and extracted three times with ethyl acetate (50 mL each).
  • the foUowing compounds were prepared in analogy to the method as described above:
  • triphenylphosphine (4 mg, 0.01 mmol), bis(triphenylphosphine)-paUadium(II)chloride (16 mg, 0.02 mmol), copper(I)- iodide (1 mg, 0.01 mmol) and triethyl amine (0.10 mL, 0.69 mmol) were dissolved in 2 mL dry THF. This mixture was also evacuated and backfiUed with argon several times to remove oxygen from the solution.
  • 2-CUoro-6-[2-methyl-4-(2-me1i ⁇ yl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrazine (27)(300 mg, 0.968 mmol) was dissolved in 5 mL dry tetrahydrofuran. Dimethylzinc (1.2 mL, 2M in toluene) and tetrakis(triphenylphosphin)paUadium (23 mg, 0.02 mmol) were added. The reaction mixture was refluxed for 2h and poured into 50 mL sat. sodium bicarbonate solution. The mixture was extracted three times with ethyl acetate (50 mL each).
  • the foUowing compounds were prepared in analogy to the method as described above:
  • Diisopropylamine (0.260 mg, 2.6 mmol) was dissolved in 5 mL dry tetrahydrofurane, n- butyUithium (1.6 mL, 1.6 M in hexane, 2.6 mmol) were added at -78°C and the mixture was kept at -78°C for 10 min.
  • 4-[l-(4-Fluoro-phenyl)-2-methyl-lH-imidazol-4-ylethyn- yl] -2-methyl-pyridine (1) 500 mg, 1.72 mmol
  • 5 mL dry tetrahydrofurane was added at -78°C and stirring was continued for 45 min at this temperature.
  • Tablets of the foUowing composition are produced in a conventional manner: mg/Tablet Active ingredient 100
  • Tablets of the foUowing composition are produced in a conventional manner: mg/Tablet Active ingredient 200
  • Capsules of the foUowing composition are produced: - 44 - mg/Capsule
  • the active ingredient having a suitable particle size, the crystaUine lactose and the microcrystaUine ceUulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed.
  • the final mixture is filled into hard gelatine capsules of suitable size.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

4-[1-Aryl-imidazol-4-ylethynyl]-2-alkyl-pyridine and 1-heteroaryl-imidazol-4-ylethynyl]-2-alkyl-pyridine derivatives and pharmaceutically acceptable salts thereof for the treatment or prevention of disorders mediated full or in part by metabotropic glutamate receptor 5, e.g. acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain and drug dependency.

Description

Imidazol-4-yl-ethynyl-pyridine derivatives
The present invention relates to novel imidazole derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
More particularly the present invention provides in a first aspect novel 4- [1 -aryl and 1- heteroaryl-imidazol-4-ylethynyl] -2-alkyl-pyridine derivatives as well as pharmaceutically acceptable salts thereof.
More particularly the present invention provides a compound of formula I
Figure imgf000002_0001
wherein R1 is Q- alkyl;
R2 is Ci-C6alkyl or C3~C12cycloalkyl;
R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, C alkyl, S-CrCβalkyl, - alkyl-halogen, Cι-C6alkoxy, halogen-Ci-C6alkoxy, C3-Cι2cycloalkyl, C2- Cπheterocycloalkyl, CrCβalkylamino, di-Ci-Cβalkylamino, -Cealkoxyamino, ( -
C6alko y)C C6alkylamino, Cs-C^cycloalkylamino, benzylamino and cyano; and R4 is hydrogen, C(O)H or CH2R5 wherein R5 is hydrogen, OH, CrC6alkyl or C3-
Cι2cycloalkyl.
In one embodiment the present invention provides a compound of formula I*
Figure imgf000003_0001
wherein
R1 signifies lower alkyl; R2 signifies lower alkyl; R3 signifies aryl or heteroaryl, optionally substituted, preferably by one, two or three substituents, selected from the group consisting of halogen, lower alkyl, lower alkyl- halogen or cyano; as well as to pharmaceutically acceptable salts thereof.
It has now surprisingly been found that the compounds of general formula I are metabo- tropic glutamate receptor 5 antagonists. Compounds of formula I are distinguished by having valuable therapeutic properties. They can be used in the treatment or prevention of mGluR5 receptor mediated disorders.
In the central nervous system (CNS) the transmission of stimuli takes place by the interaction of a neurotransmitter, which is sent out by a neuron, with a neuroreceptor.
Glutamate is the major excitatory neurotransmitter in the brain and plays a unique role in a variety of central nervous system (CNS) functions. The glutamate-dependent stimulus receptors are divided into two main groups. The first main group, namely the ionotropic receptors, forms ligand-controlled ion channels. The metabotropic glutamate receptors (mGluR) belong to the second main group and, furthermore, belong to the family of G- protein coupled receptors.
At present, eight different members of these mGluR are known and of these some even have sub-types. According to their sequence homology, signal transduction mechanisms and agonist selectivity, these eight receptors can be sub-divided into three sub-groups:
mGluRl and mGluR5 belong to group I, mGluR2 and mGluR3 belong to group II and mGluR4, mGluR6, mGluR7 and mGluRS belong to group III.
Ligands of metabotropic glutamate receptors belonging to the first group can be used for the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits, as well as chronic and acute pain.
Other treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are ischemia, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopafhic parkinsonism or parkin- sonism caused by medicaments as well as conditions which lead to glutamate- deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, drug abuse/dependance such as nicotine addiction, opiate addiction, and alcohol abuse, anxiety, vomiting, dyskinesia and depressions.
Disorders mediated full or in part by mGluR5 are for example acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain and drug dependency [Expert Opin. Ther. Patents 12:12 (2002)].
Selective mGluR5 antagonists are especially useful for the treatment of anxiety and pain.
Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts, the above-mentioned compounds as pharmaceutically active substances and their production. Further objects of the invention are medicaments based on a compound in accordance with the invention and their manufacture as well as the use of the compounds in the control or prevention of mGluR5 receptor mediated disorders, and, respectively, for the production of corresponding medicaments.
The following definitions of general terms used in the present description apply irrespec- tive of whether the terms in question appear alone or in combination. The term "lower alkyl" used in the present description denotes straight-chain or branched saturated hydrocarbon residues with 1 to 6 carbon atoms, preferably with 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl and the like. The term „cycloalkyl" used in the present description denotes cyclic saturated hydrocarbon residues with 3 to 12 carbon atoms. Examples for cycloallcyl include cyclopropyl, cyclobutyl and cyclopentyl.
Examples for -Csalko y include mefhoxy, methoxyethyl and methoxyethoxy. Examples for halogenmethoxy include trifluoromethoxy. Examples for C2-CπheterocycloaIkyl include pyrrolidinyl, morpholinyl and thiomorpho- linyl.
Examples for -Csalkylamino include methylamino and ethylamino. Examples for di- - C6al_kylamino include dimethylamino. Examples for -Cealkoxyamino include methoxy- ethylamino. Examples for (C1-C6alkoxy)C1-C6aIkylamino include (methoxyethyl)methyl- amino. Examples for methoxycycloalkylamino include cyclopropylamino.
The term "halogen" denotes fluorine, chlorine, bromine and iodine.
"Aryl" represents an aromatic carbocyclic group consisting of one individual ring, or one or more fused rings in which at least one ring is aromatic in nature. Examples for aryl in- elude phenyl. Examples for substituted aryl include fluorophenyl, difluorophenyl, chloro- phenyl, dichlorophenyl, chlorofluorophenyl, cyanophenyl, methylphenyl, methoxyphenyl, fluoromethylphenyl, trifluoromethylphenyl and trifluoromethoxyphenyl.
The term "heteroaryl" refers to an aromatic 5- or 6-membered ring or one or more fused rings containing one or more heteroatoms selected from nitrogen, oxygen or sulphur. Examples of such heteroaryl groups are pyrimidinyl, pyrazinyl, pyridazinyl, pyridinyl and indolyl, e.g. pyridin-4-yl, pyridin-2-yl, pyrazin-2-yl and pyrimidin-2-yl. Examples for substituted heteroaryl include methylpyrimidinyl, dimethylpyrimidinyl, trifluoromethylpyri- midinyl, mefhoxypyrimidinyl, methoxyethoxypyrimidinyl, ethylpyrimidinyl, fluoropyri- midinyl, chloropyrimidinyl, bromopyrimidinyl, methylsulfanylpyrimidinyl, cyclopropyl- pyrimidinyl, methylpyrazinyl, cyclopropylpyrazinyl, chloropyrazinyl, methoxypyrazinyl, methoxyethoxypyrazinyl, methylaminopyrazinyl, dimethylaminopyrazinyl, cyclopropyl- aminopyrazinyl, morpholinylpyrazinyl, fluoropyridinyl, chloropyridinyl, bromopyridinyl, iodopyridinyl, methylpyridinyl, trifluoromethylpyridinyl, trifluoromethylmethylpyridinyl, cyclopropylpyridinyl, butylpyridinyl, methoxypyridinyl, dimethylaminopyridinyl, methyl- aminopyridinyl, ethylaminopyridinyl, pyrrolidinylpyridinyl, morpholinylpyridinyl, thio- morpholinylpyridinyl, (methoxyethyl) methylaminopyridinyl, methoxyethylaminopyri- dinyl, benzylaminopyridinyl and methyl- lH-indolyl.
The term "pharmaceutically acceptable salt" refers to any salt derived from an inorganic or organic acid.
"Pharmaceutically acceptable salts" of a compound means salts that are pharmaceutically acceptable, which are generally safe, non-toxic, and neither biologically nor otherwise undesirable, and that possess the desired pharmacological activity of the parent compound. These salts are derived from an inorganic or organic acid. If possible, compounds of formula I may be converted into pharmaceutically acceptable salts.
It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) of the same acid addition salt.
Examples for pharmaceutically acceptable acid addition salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucohep tonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaph- thoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, dibenzoyl-L-tartaric acid, tartaric acid, p-toluene-sulfonic acid, trimethylacetic acid, trifluoroacetic acid, and the like.
Preferred compounds of formula I* are those, in which R1 and R2 are both methyl.
Especially preferred are those compounds from this group, in which R3 is substituted phenyl, wherein the substitution is fluoro, chloro, cyano or CF3.
The following are examples of compounds, wherein the substitution is fluoro or chloro: 4-[l-(4-fluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl]-2-methyl-pyridine, 4- [l-(3,4-dichloro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, HCl 4-[l-(2,4-difluoro-phenyl)-2-me1_hyl-lH-imidazol-4-ylethynyl]-2-methyl-pyridine, or 4- [ 1 - (3,4-difluoro-phenyl) -2-methyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine.
Examples of compounds, wherein the substitution is cyano, are as follows: 4- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -benzonitrile, or 3-[2-methyl-4-(2-mefhyl-pyridin-4-ylethynyl)-imidazol-l-yl]-benzonitrile.
The following is an example of compounds, wherein the substitution is CF3: 2-me1iyl-4-[2-methyl-l-(3-frifluoromethyl-phenyl)-lH-imidazol-4-ylethynyl]-pyridine.
Especially preferred are further those compounds, wherein R1 and R2 are both methyl and R3 is pyrimidinyl, for example the following compound: 2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyrimidine. In one embodiment the present invention provides a compound of formula I wherein R1 is methyl, and R2, R3 and R4 independently are as defined above or hereinafter.
In one embodiment the present invention provides a compound of formula I wherein R2 is Ci-Cgalkyl. In another embodiment the present invention provides a compound of formula I wherein R2 is methyl or isopropyl. In another embodiment the present invention provides a compound of formula I wherein R2 is cyclopropyl. In all the above embodiments R , R3 and R4 independently are as defined above or hereinafter.
In one embodiment the present invention provides a compound of formula I wherein R3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halo- gen, C Cδalkyl, S-Ci-Cgalkyl, Ci-C6aIkyl-halogen, Cι-C6alkoxy, halogen-Ci-Cealkoxy, C3- C12cycloalkyl, C2-Cnheterocycloalkyl, CrCgalkylamino, di- -Cδalkylamino, CrCgalkoxy- amino, (C1-C6alkoxy)C1-C6alkylamino, C3-Cι2cycloaIkylamino, benzylamino and cyano. In another embodiment the present invention provides a compound of formula I wherein R3 is phenyl or phenyl substituted by one, two or three substituents selected from halogen, Ci-Cgalkyl, S- -Cgalkyl, Ci-Cgalkyl-halogen, Ci-C6alkoxy, halogen- -Cgalkoxy, C3-
Cι2cycloalkyl, C -Cπheterocycloalkyl, -Cgall ylamino, di-Ci-Cgalkylamino, Ci-C6alkoxy- amino, (C1-C6alkoxy)C1-C6alkylamino, C3-Cι2cycloalkylamino, benzylamino and cyano. In another embodiment the present invention provides a compound of formula I wherein R3 is phenyl or phenyl substituted by one or two substituents selected from halogen, C Cgalkyl, CrCgalkyl-halogen, -Cgalkoxy, halogen- -Cgalkoxy and cyano. In another embodiment the present invention provides a compound of formula I wherein R3 is phenyl substituted by one or two substituents selected from halogen, -Cgalkyl, - C6alkyl-halogen, Ci-Cgalkoxy, halogen-Ci-C6aIkoxy and cyano. In another embodiment the present invention provides a compound of formula I wherein R3 is phenyl substituted by one or two substituents selected from fluoro, chloro, methyl, trifluoromethyl, methoxy, trifluoromethoxy and cyano. In another embodiment the present invention provides a compound of formula I wherein R3 is fluorophenyl, difluorophenyl, chlorophenyl, di- chlorophenyl, cyanophenyl, trifluoromethylphenyl, fluoro-methylphenyl, chloro-fluoro- phenyl, methylphenyl, methoxyphenyl or trifluoromethoxyphenyl. In all the above em- , bodiments R1, R2 and R independently are as defined above or hereinafter.
In one embodiment the present invention provides a compound of formula I wherein R3 is unsubstituted heteroaryl or heteroaryl substituted by one, two or three substituents selected from the group consisting of halogen, Ci-Cgalkyl, S-Ci-Cgalkyl, -Cgalkyl-halo- gen, Ci-Cgalkoxy, halogen-CrCgalkoxy, C3-Cι2cycloaIkyl, C2-Cπheterocycloalkyl, Q- Cgalkylamino, di-Ci-Cgalkylamino, Ci-Cgalkoxyamino, (Ci-Cgalkoxy)Cι-C6alkylamino, C3-Ci2cycloalkylamino, benzylamino and cyano. In another embodiment the present invention provides a compound of formula I wherein R3 is unsubstituted pyrimidinyl, unsubstituted pyrazinyl or unsubstituted pyridinyl. In another embodiment the present invention provides a compound of formula I wherein R3 is heteroaryl selected from pyrimi- dinyl, pyrazinyl, pyridinyl and indolyl wherein the heteroaryl is substituted by one or two substituents selected from halogen, Ci-Cgalkyl, S-CrCgalkyl, Ci-Cgalkyl-halogen, Q- Cgalkoxy, C3-C12cycloalkyl, C2-Cnheterocycloalkyl, -Cgalkylamino, di- -Cgalkylamino, CrCgalkoxyamino, (Ci-Cgalkoxy)Cι-Cgalkylamino, C3-Cι2cycloalkylamino and benzylamino. In another embodiment the present invention provides a compound of formula I wherein R3 is pyrimidinyl substituted by one or two substituents selected from halogen, Ci-Cgalkyl, S-Ci-Cδalkyl, Ci-Cgalkyl-halogen, -Cgalkoxy and C3-Cι2cycloalkyl; or pyrazinyl substituted by one substituent selected from halogen, Ci-Cgalkyl, Ci-Cgalkoxy, C3-C12cycloalkyl, C2-Cπheterocycloalkyl, Ci-Cgalkylamino, di-Ci-Cgalkylamino and C3- C12cycloalkylamino; or pyridinyl substituted by one or two substituents selected from halogen, d-Cgalkyl, CrCgalkyl-halogen, Q-Cgalkoxy, C3-C12cycloalkyl, C2-Cπhetero- cycloalkyl, C Cgalkylamino, di-CrCgalkylamino, CrCgalkoxyamino, (CrCgalkoxy)Cr Cgalkylamino and benzylamino; or methyl- lH-indolyl. In another embodiment the present invention provides a compound of formula I wherein R3 is methylpyrimidinyl, ethylpyrimidinyl, dimethylpyrimidinyl, trifluoromethylpyrimidinyl, methoxypyrimidinyl, methoxyethoxypyrimidinyl, fluoropyrimidinyl, chloropyrimidinyl, bromopyrimidinyl, methylsulfanylpyrimidinyl, cyclopropylpyrimidinyl, methylpyrazinyl, cyclopropylpyr- azinyl, mefhoxypyrazinyl, chloropyrazinyl, methylaminopyrazinyl, dimethylaminopyr- azinyl, cyclopropylpyrazinyl, mefhylpyridinyl, butylpyridinyl, fluoropyridinyl, chloro- pyridinyl, bromopyridinyl, iodopyridinyl, trifluoromethylpyridinyl, (trifluoromethyl) - methylpyridinyl, cyclopropylpyridinyl, methoxypyridinyl, methoxyethoxypyrazinyl, methylaminopyridinyl, ethylaminopyridinyl, dimethylaminopyridinyl, pyrrolidinylpyri- dinyl, morpholinylpyridinyl, thiomorpholinylpyridinyl, (methoxyethyl)methylamino- pyridinyl, methoxyethylaminopyridinyl, benzylaminopyridinyl or methyl- lH-indolyl. In all the above embodiments R1, R2 and R4 independently are as defined above or herein- after.
In one embodiment the present invention provides a compound of formula I wherein R4 is hydrogen, C(O)H or CH3. In another embodiment the present invention provides a compound of formula I wherein R4 is hydrogen. In all the above embodiments R1, R2 and R3 independently are as defined above or hereinafter.
In one embodiment the present invention provides a compound of formula I wherein R1 is methyl;
R2 is Ci-Cgalkyl or C3-C12cycloalkyl;
R3. is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, CrCgalkyl, S-CrCgalkyl, - Cgalkyl-halogen, CrCgalkoxy, halogen-CrCgalkoxy, C3-C12cycloalkyl, C2-
Cπheterocycloalkyl, CrCgalkylamino, di-CrCgalkylamino, CrC6alkoxyamino, (Q-
Cgalkoxy) CrCgalkylamino, C3-C12cycloalkylamino, benzylamino and cyano; and R4 is hydrogen, C(O)H or CH2R5 wherein R5 is hydrogen, OH, CrCgalkyl or C3-
C12cycloalkyl.
In another embodiment the present invention provides a compound of formula I wherein R1 is methyl;
R2 is methyl, isopropyl or cyclopropyl; R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, CrCgalkyl, S-Ci-Cgalkyl, - Cgalkyl-halogen, CrCgalkoxy, halogen-CrCgalkoxy, C3-C12cycloalkyl, C2-
Cπheterocycloalkyl, CrCgalkylamino, di-Ci-Cgalkylamino, CrCgalkoxyamino, ( -
Cgalkoxy) CrCgalkylamino, C3-C12cycloalkylamino, benzylamino and cyano; and R4 is hydrogen, C(O)H or CH2R5 wherein R5 is hydrogen, OH, CrCgalkyl or C3-
C12cycloalkyl.
In still another embodiment the present invention provides a compound of formula I wherein
R1 is methyl;
R2 is methyl, isopropyl or cyclopropyl;
R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, CrCgalkyl, S-CrCgalkyl, Ci-
Cgalkyl-halogen, Ci-Cgalkoxy, halogen-CrCgalkoxy, C3-Cι2cycloalkyl, C2- Cπheterocycloalkyl, CrCgalkylamino, di-Ci-Cgalkylamino, CrCgalkoxyamino, (Ci- Cgalkoxy) CrCgalkylamino, C3-Ci2cycloal_kylamino, benzylamino and cyano; and
R4 is hydrogen, C(O)H or methyl.
In still another embodiment the present invention provides a compound of formula I wherein
R1 is methyl;
R2 is methyl, isopropyl or cyclopropyl;
R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, Ci-Cgalkyl, S-Ci-Cgalkyl, Q- C6alkyl-halogen, Ci-Cgalkoxy, halogen-Ci-Cgalkoxy, C3-Cι2cycloalkyl, C2- Ciiheterocycloalkyl, CrCgalkylamino, di-Ci-Cgalkylamino, Ci-Cgalkoxyamino, (Q- Cgalkoxy)Cι-Cgalkylamino, Q-Cncydoalkylamino, benzylamino and cyano; and R is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R and R are methyl;
R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, Ci-Cgalkyl, S-CrCgalkyl, Q- Cgalkyl-halogen, Q-Cgalkoxy, halogen-Q-Cgalkoxy, C3-C12cycloalkyl, C2-
Qiheterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkylamino, Cι-C6alkoxyamino, (Q- Cgalkoxy)Q-Cgalkylamino, C3-Cι2cycloalkylamino, ben2ylamino and cyano; and R is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl;
R3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halogen, Q-Cgalkyl, S-CrCgalkyl, Q-Cgalkyl-halogen, Ci-Cgalkoxy, halogen-Q- Cgalkoxy, Q-Cncycloalkyl, C2-Qiheterocycloalkyl, Ci-Cgalkylamino, di-Q-Cgalkyl- amino, CrCgalkoxyamino, (CrCgalkoxy)Q-Cgalkylamino, C3-Cι2cycloalkylamino, benzylamino and cyano; and R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein R1 and R2 are methyl;
R3 is phenyl or phenyl substituted by one, two or three substituents selected from halogen, Ci-Cgalkyl, S-Ci-Cgalkyl, Q-Cgalkyl-halogen, Ci-Cgalkoxy, halogen-Ci- Cgalkoxy, C3-Q2cycloalkyl, -Qiheterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkyl- amino, CrCgalkoxyamino, (Q-Cgalkoxy)Ci-Cgalkylamino, C3-Cι2cycloalkylamino, benzylamino and cyano; and
R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl; R3 is phenyl or phenyl substituted by one or two substituents selected from halogen, Q-
Cgalkyl, Q-Cgalkyl-halogen, Q-Cgalkoxy, halogen-Q-C6alkoxy and cyano; and R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl;
R3 is phenyl substituted by one or two substituents selected from fluoro, chloro, methyl, trifluoromethyl, methoxy, trifluoromethoxy and cyano; and R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl;
R3 is fluorophenyl, difluorophenyl, chlorophenyl, dichlorophenyl, cyanophenyl, tri- fluoromethylphenyl, fluoro-methylphenyl, chloro-fluorophenyl, methylphenyl, mefh- oxyphenyl or trifluoromethoxyphenyl; and
R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl; R3 is unsubstituted heteroaryl or heteroaryl substituted by one, two or three substituents selected from the group consisting of halogen, Ci-Cgalkyl, S-Q-Cgalkyl, Ci-Cgalkyl- halogen, CrCgalkoxy, halogen-Ci-Cgalkoxy, Q-Cncycloalkyl, C -Qιheterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkylamino, Q-Cgalkoxyamino, (Q-CgalkoxyJQ-Cgalkyl- amino, C3-Q2cycloalkylamino, benzylamino and cyano; and R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl;
R3 is unsubstituted pyrimidinyl, unsubstituted pyrazinyl or unsubstituted pyridinyl; and R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl; R3 is heteroaryl selected from pyrimidinyl, pyrazinyl, pyridinyl and indolyl wherein the heteroaryl is substituted by one or two substituents selected from halogen, Q-Cgalkyl, S-Q-Cgalkyl, Q-Cgalkyl-halogen, Q-Cgalkoxy, C3-Cι2cycloalkyl, Q-Qiheterocyclo- alkyl, Q-Cgalkylamino, di-Q-Cgalkylamino, Q-Cgalkoxyamino, (Q-Cgalkoxy) Q- Cgalkylamino, C3-Cι2cycloalkylamino and benzylamino; and
R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl; R3 is pyrimidinyl substituted by one or two substituents selected from halogen, Ci- Cgalkyl, S-Q-Cgalkyl, Ci-Cgalkyl-halogen, Q-Cgalkoxy and C3-C12cycloalkyl; or pyrazinyl substituted by one substituent selected from halogen, Q-Cgalkyl, Ci-Cgalkoxy, C3-Q2cycloalkyl, C2-Qιheterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkylamino and C3-Q2cycloalkylarnino; or pyridinyl substituted by one or two substituents selected from halogen, Q-Cgalkyl, Q-Cgalkyl-halogen, Ci-Cgalkoxy, Q-Cπcycloalkyl,
C2-Qιheterocycloalkyl, CrCgalkylamino, di-Q-Cgalkylamino, CrCgalkoxyamino, (Cι-Cgalkoxy)Ci-Cgalkylamino and benzylamino; or methyl- lH-indolyl; and
R4 is hydrogen.
In still another embodiment the present invention provides a compound of formula I wherein
R1 and R2 are methyl;
R3 is methylpyrimidinyl, ethylpyrimidinyl, dimethylpyrimidinyl, trifluoromethylpyri- midinyl, methoxypyrimidinyl, methoxyethoxypyrimidinyl, fluoropyrimidinyl, chloropyrimidinyl, bromopyrimidinyl, methylsulfanylpyrimidinyl, cyclopropylpyrimidinyl, methylpyrazinyl, cyclopropylpyrazinyl, methoxypyrazinyl, chloropyrazinyl, methyl- aminopyrazinyl, dimethylaminopyrazinyl, cyclopropylpyrazinyl, methylpyridinyl, butylpyridinyl, fluoropyridinyl, chloropyridinyl, bromopyridinyl, iodopyridinyl, tri- fluoromethylpyridinyl, (trifluoromethyl) methylpyridinyl, cyclopropylpyridinyl, meth- oxypyridinyl, methoxyethoxypyrazinyl, methylaminopyridinyl, ethylaminopyridinyl, dimethylaminopyridinyl, pyrrolidinylpyridinyl, morpholinylpyridinyl, thiomorpho- linylpyridinyl, (methoxyethyl)methylaminopyridinyl, methoxyethylaminopyridinyl, benzylaminopyridinyl or methyl- lH-indolyl; and
R4 is hydrogen.
Examples of compounds of formula I include 4-[l-(4-fluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, -[l-(3,4-dichloro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine hydro- chloride, -[l-(2,4-difluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl]-2-methyl-pyridine, - [l-(3,4-difluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, -[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-benzonitrile, -[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-benzonitrile, -methyl-4-[2-methyl-l-(3-trifluorome1_hyl-phenyl)-lH-imidazol-4-ylethynyl]-pyridine, - [2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrimidine, -[l-(4-chloro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, - [2-cyclopropyl- 1- (4-fluoro-ρhenyl) - lH-imidazol-4-ylethynyl] -2-methyl-pyridine, -[l-(3-fluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, - [ l-(3,5-difluoro-phenyl)-2-methyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine, - [ l-(3-fluoro-4-methyl-phenyl) -2-methyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine, -[l-(3-cUoro-4-fluoro-phenyl)-2-methyl-lH-imidazol-4-yle1_hynyl]-2-methyl-pyridine, -methyl-4-(2-mefhyl-l-p-tolyl-lH-imidazol-4-ylethynyl)-pyridine, - [l-(4-methoxy-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, -methyl-4-[2-methyl-l-(4-trifluoromethyl-phenyl)-lH-imidazol-4-ylethynyl]-pyridine, ,6-dimefhyl-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrimidine, -methyl-2- [2-methyl-4-(2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyrimidine, -[2-methyl-4-(2-met_hyl-pyridin-4-yletxιynyl)-imidazol-l-yl]-4-trifluoromethyl-pyrimi- dine, -methoxy-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrimidine, -ethyl-2-[2-methyl-4-(2-metih.yl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrimidine, -fluoro-2-[2-me1_hyl-4-(2-methyl-pyridιn-4-yle ynyl)-imidazol-l-yl]-pyrimidine, -[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrazine, -methyl-5-[2-memyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrazine, -methyl-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrazine, -cyclopropyl-6- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyrazine, -chloro-6- [2-methyl-4- (2-methyl-pyridm-4-ylethynyl) -imidazol- 1 -yl] -pyrazine, -methoxy-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrazine, -chloro-4-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrimidine, -cUoro-2-[2-methyl-4-(2-methyl-ρyridin-4-ylethynyl)-imidazol-l-yl]-pyrimidine, -[2-me1iιyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-2-methylsulfanyl-pyrimi- dine, - [2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -2-trifluoromefhyl-pyrimi- dine, -[2-metiιyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridine, 6-£luoro-2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyridine, 2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-6-methylpyridine, 2-[2-isopropyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-6-methylpyridine, 2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -6-methyl-4-trifluoro- methyl-pyridine,
2-cyclopropyl-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyridine,
2-bu1yl-6-[2-metfryl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyridine,
2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -6-trifluoromethyl-pyridine,
2-[2-isopropyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-6-trifluoromethyl-pyri- dine,
2-methoxy-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridine, 2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -5-methyl-pyridine, 2-[2-isopropyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-5-methyl-pyridine, 5-cHoro-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridine, 5-bromo-2- [2-mefhyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1-yl] -pyridine, 4-iodo-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridine, 2-[2-methyl-4-(2-me1±ιyl-pyridin-4-ylethynyl)-imidazol-l-yl]-4-methyl-pyridine, 2- [2-methyl-4-(2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -4-trifluoromethyl-pyridine, 2-methoxy-4- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyridine, 2-chloro-5-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyridine, 2-bromo-5- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyridine, 5-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -2-methyl-pyridine, 2-cyclopropyl-5-[2-metfryl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyridine, 2-butyl-5-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridine, 3-fluoro-5-[2-methyl-4-(2-methyl-pyridm-4-ylethynyl)-imidazol-l-yl]-pyridine, 3-chloro-5-[2-methyl-4-(2-me1_hyl-pyridin-4-yletfrynyl)-imidazol-l-yl]-pyridine, dimethyl-{5-[2-memyl-4-(2-me1_hyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridin-3-yl}- amine, dimethyl-{6-[2-methyl-4-(2-me1iιyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridin-2-yl}- amine, dime1fryl-{6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrazin-2-yl}- amine, eliyl-{5-[2-methyl-4-(2-metfryl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridin-3-yl}-amine, metfryl-{6-[2-metfryl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridin-2-yl}- amine, methyl-{6- [2-mefhyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol- 1-yl] -pyrazin-2-yl}- amine, cyclopropyl-{6-[2-methyl-4-(2-meliyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrazin-2-yl}- amine, l-{5-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridin-3-yl}-pyrroli- dine, l-{6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridin-2-yl}-pyrroli- dine, 1 -{3 - [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyridin-5-yl} -piperidine, 4-{6-[2-methyl-4-(2-methyl-pyridin-4-ylefhynyl)-imidazol-l-yl]-pyridin-2-yl}-morpho- line, 4-{6-[2-methyl-4-(2-methyl-pyridin-4-ylefhynyl)-imidazol-l-yl]-pyrazin-2-yl}-morpho- line, 4-{6- [2-methyl-4- (2-methyl-pyridin-4-ylefhynyl)-imidazol- 1-yl] -pyridin-2-yl}-thiomor- pholine, (2-metfroxy-ethyl)-methyl-{6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l- yl] -pyridin-2-yl} -amine,
(2-metfroxy-ethyl)-{6-[2-metfryl-4-(2-memyl-pyridin-4-yle1_hynyl)-imidazol-l-yl]-pyr^ din-2-yl}-amine, 4-cyclopropyl-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyridine, 5-cyclopropyl-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridine, 4-fluoro-6- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyrimidine, 5-bromo-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrimidine, 5-methyl-2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyrimidine, 2-cyclopropyl-4-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrimidine, 4-cyclopropyl-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrimidine, 2-(2-methoxy-ethoxy)-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrazine, 2-(2-methoxy-e1_hoxy)-6-[2-methyl-4-(2-met^^ pyridine, 2-methyl-4- [2-methyl- l-(3-trifluoromethoxy-phenyl)- lH-imidazol-4-ylethynyl] -pyridine, l-methyl-5-[2-metfryl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-lH-indole, benzyl- { 5 - [2-methyl-4- ( 2-mefhyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyridin-3 -yl} - amine, 4- [ 1 -(4-fluoro-phenyl) -2,5-dimethyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine and' 3-(4-fluoro-phenyl)-2-methyl-5-(2-methyl-pyridin-4-ylethynyl)-3H-imidazole-4-carb- aldehyde. In one embodiment the present invention provides a compound of formula I selected from
4- [ 1 - (4-fluoro-phenyl) -2-methyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine, 4- [ 1 - (3 ,4-dichloro-phenyl) -2-methyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine hydrochloride,
4- [ 1 - (2,4-difluoro-phenyl)-2-methyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine, 4-[l-(3,4-difluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, 4-[2-methyl-4-(2-methyl-pyridin-4-ylefhynyl)-imidazol-l-yl]-benzonitrile, 3 - [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -benzonitrile, 2-methyl-4-[2-methyl-l-(3-trifluoromethyl-phenyl)-lH-imidazol-4-ylethynyl] -pyridine, 2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl)-imidazol- 1 -yl] -pyrimidine, 2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-4-trifluoromethyl- pyrimidine, 4-methoxy-2- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyrimidine, 2-cyclopropyl-6- [2-mefhyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrazine, 4-chloro-2- [2-me1fryl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol- 1-yl] -pyrimidine, 2-cyclopropyl-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-ρyridine, 2-methoxy-6-[2-metfryl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridine, dimethyl-{6-[2-methyl-4-(2-metfryl-pyridin-4-yle1_hynyl)-imidazol-l-yl]-pyridin-2-yl}- amine, l-methyl-5-[2-me1_hyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-lH-indole, 4- [ l-(4-fluoro-phenyl)-2,5-dimethyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine and 3-(4-fluoro-ρhenyl)-2-methyl-5-(2-mefhyl-pyridin-4-ylethynyl)-3H-imidazole-4- carbaldehyde.
The present invention also provides a process for the production of a compound of formula I
Figure imgf000016_0001
wherein
R1 is Q-Cgalkyl; R2 is Ci-Cgalkyl or C3-C12cycloaIkyl; R3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halogen, Q-Cgalkyl, S-Q-Cgalkyl, Ci-Cgalkyl-halogen, Q-Cgalkoxy, halogen-Ci- Cgalkoxy, C3-Q2cycloalkyl, Q-Qiheterocycloalkyl, Q-Cgalkylamino, di-Q-Cgalkylamino, CrCgalkoxyamino, (Q-Cgalkoxy)CrCgalkylamino, Q-Cπcycloalkylamino, benzylamino and cyano, unsubstituted heteroaryl or heteroaryl substituted by one, two or three substituents selected from the group consisting of halogen, Q-Cgalkyl, S- Q-Cgalkyl, Q -Cgalkyl-halogen, Q-Cgalkoxy, halogen-Q-Qalkoxy, C3-Q2cycloalkyl, C2-Qιheterocycloalkyl, CrCgalkylamino, di-Ci-Cgalkylamino, Q-Cgalkoxyamino, (Cι-Cgalkoxy)Q-Cgalkylamino, C3-Q2cycloalkylamino, benzylamino and cyano; and R4 is hydrogen, C(O)H or CH2R5 wherein R5 is hydrogen, OH, Q-Cgalkyl or C3- Cι2cycloalkyl; which process comprises reacting
(a) a compound of formula II
Figure imgf000017_0001
wherein R1, R2 and R4 have the meanings as defined above, with a compound of formula III
R3-Z (III) wherein R3 has the meanings as defined above and Z is halogen or B(OH)2; or (b) a compound of formula IV
Figure imgf000017_0002
wherein R2, R3 and R4 have the meanings as defined above, with a compound of formula V
Figure imgf000017_0003
wherein R1 has the meanings as defined above and X is halogen; or (c) a compound of formula VI
Figure imgf000018_0001
wherein R , R and R4 have the meanings as defined above and hal is halogen, with a compound of formula VII
Figure imgf000018_0002
wherein R1 has the meaning as defined above and Y is trimethylsilyl or hydrogen.
The reaction as described in (a) maybe carried out in accordance with standard procedures, e.g. by arylation of a compound of formula II using an aromatic boronic acid and a copper catalyst in a solvent like dichloromethane or tetrahydrofurane [see e.g. Colmann et al., Org. Lett. 2:1233 (2000)] or by heating a compound of formula II and a compound of formula III wherein Z is halogen with a base like potassium carbonate or cesium carbonate in a solvent like dimethylformamide, or Pd catalyzed according to Buchwald conditions [see e.g. Example 8; Buchwald et al., Tetrahedron Lett. 40:2657 (1999)] . The reaction as described in (b) may be carried out by a Sonogashira coupling of a compound of formula IV and a compound of formula V in the presence of, e.g., Cul, (Ph3P)2PdCl , Et^N in a solvent like tetrahydrofuran or dimethylformamide [Sonogashira et al, Synthesis 777 (1977)]. In one embodiment the meaning X in compounds of formula V is bromine or iodine. The reaction as described in (c) above may, e.g. be carried out in the presence of Cul, (Ph.3P)2PdCl2, Et3N, n-Bu F in a solvent like tetrahydrofuran or dimethylformamide.
The salt forms are made by standard procedures known to the skilled artisan.
The compounds of formulae II, IV, VI und VII are novel and also an embodiment of the present invention.
The compounds of formulae III and V are commercially available or their preparation is known to the skilled artisan.
The compounds of formula II may be prepared by reacting a compound of formula VIII
Figure imgf000019_0001
wherein R2 and R4 have the above meanings and hal is halogen, with a compound of formula VII as above.
The compounds of formula VIII may be prepared as described e.g. in Cliff and Pyne [Synthesis 681-682 (1994)].
The compounds of formula IV maybe prepared by reacting a compound of formula IX
R ,2- « ° (IX)
*# "
R3 R4 wherein R2, R3 and R4 have the meanings as defined above, with dimethyl (l-diazo-2-oxopropyl)phosphonate as described in Ohira [Synth. Comm. 19:561-564 (1989)].
Compounds of formula VI may be prepared by reacting a compound of formula VIII as above with a compound of formula X
R3-B(OH)2 (X) wherein R3 has the meanings as defined above.
The reaction may take place by arylation of a compound of formula VIII using an aromatic boronic acid (compound of formula X) and a copper catalyst in a solvent like dichloromethane or tetrahydrofurane under an oxygen atmosphere [see e.g. Colmann et al., Org.Lett. 2:1233 (2000)].
Compounds of formula VII may be prepared by reacting a compound of formula V as above with a compound of formula XI
^ (XI)
The reaction may take place by a Sonogashira coupling in the presence of eg. Cul, (Ph3P)2PdCl2, EtaN in a solvent like tetrahydrofuran or dimethylformamide [Sonogashira et al., Synthesis 777 (1977)].
Compounds of formula IX may be prepared by oxidizing a compound of formula XII
Figure imgf000020_0001
according to methods known to the skilled artisan.
Compounds of formula XII ma be prepared by deprotecting a compound of formula XIII
Figure imgf000020_0002
according to methods known to the skilled artisan.
Compounds of formula XIII may be prepared by alkylating a compound of formula XIV
Figure imgf000020_0003
with an alkylating agent of formula XVa
R2-hal (XVa)
according to methods known to the skilled artisan.
Starting compounds of formula XVa are commercially available.
Compounds of formula XIV maybe prepared by treating a compound of formula XV
Figure imgf000020_0004
with tert. -butyl dimethyl silyl chloride according to methods known to the skilled artisan.
Compounds of formula XV may be prepared by treating a compound of formula XVI
Figure imgf000021_0001
with a reducing agent according to methods known to the skilled artisan.
Compounds of formula XVI maybe prepared by hydrolysing a compound of formula. XVII
Figure imgf000021_0002
according to methods known to the skilled artisan.
Compounds of formula XVII may be prepared by treating a compound of formula XVIII
R3-NH2 (XVIII) with e.g. triethyl orthoformate, ethylnitro acetate, glacial acetic acid and iron powder according to methods known to the skilled artisan.
Compounds of formula XVIII are commercially available.
The compounds of general formula I* and their pharmaceutically acceptable salts can be manufactured by two general procedures, which procedures are outlined below for compounds wherein R1 is methyl and R2 is methyl, but which procedures are applicable for all compounds according to Formula I*.
Scheme 1
"s J o S Stetepp ll
Figure imgf000021_0003
Scheme 1 contd.
Figure imgf000022_0001
Scheme 1 contd
Figure imgf000022_0002
Scheme 2
Figure imgf000022_0003
Fe
Scheme 2 contd.
Figure imgf000022_0004
Scheme 2 contd.
Figure imgf000022_0005
Scheme 2 contd.
Figure imgf000022_0006
The invention also relates to a process for preparing a compound according to general formula I* following the general procedures as outlined above for compounds of formula I* wherein R1 is methyl and R2 is methyl (R3 and R1 are designated Ar and Ar', respectively, in Scheme 2).
Moreover the invention relates also medicaments containing one or more compounds of the present invention and pharmaceutically acceptable excipients for the treatment and. prevention of mGluR5 receptor mediated disorders, such as acute and/ or chronic neurological disorders, in particular anxiety and chronic or acute pain.
The invention also relates to the use of a compound in accordance with the present invention as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and prevention of mGluR5 receptor mediated disorders as outlined above.
Pharmaceutically acceptable salts of compounds of formula I can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt. Inorganic or organic acids such as, e.g., hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I. Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation of pharmaceutically acceptable salts of acidic compounds.
The compounds of formula I and their pharmaceutically acceptable salts (hereinafter: Pharmaceutical Compounds) are, as already mentioned above, metabotropic glutamate receptor antagonists and can be used for the treatment or prevention of mGluR5 receptor mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain. Treatable neurological dis- orders are for instance epilepsy, schizophrenia, anxiety, acute, traumatic or chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Huntington's chorea, ALS, multiple sclerosis, dementia caused by AIDS, eye injuries, re- tinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, con- vulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression. Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Pharmaceutical Compounds are especially useful as analgesics. Treatable kinds of pain include inflammatory pain such as arthritis and rheumatoid disease, vasculitis, neuropathic pain such as trigeminal or herpetic neuralgia, diabetic neuropathy pain, causalgia, hyper- algesia, severe chronic pain, post-operative pain and pain associated with various condi- tions like cancer, angina, renal or billiay colic, menstruation, migraine and gout.
The pharmacological activity of Pharmaceutical Compounds was tested using the following method:
For binding experiments, cDNA encoding human mGlu 5a receptor was transiently trans- fected into EBNA cells using a procedure described by Schlaeger and Christensen [Cyto- technology 15:1-13 (1998)]. Cell membrane homogenates were stored at -80°C until the day of assay where upon they were thawed and resuspended and polytronised in 15 mM Tris-HCl, 120 mM NaCl, 100 mM KC1, 25 mM CaCl2, 25 mM MgCl2 binding buffer at pH 7.4 to a final assay concentration of 20 μg protein/ well.
Saturation isotherms were determined by addition of twelve [3H]MPEP concentrations (0.04-100 nM) to these membranes (in a total volume of 200 μl) for 1 h at 4°C. Competition experiments were performed with a fixed concentration of [3H]MPEP (2nM) and I o values of test compounds evaluated using 11 concentrations (0.3-10,O00nM). Incubations were performed for 1 h at 4° C.
At the end of the incubation, membranes were filtered onto unifilter (96-well white micro- plate with bonded GF/C filter preincubated 1 h in 0.1% PEI in wash buffer, Packard Bio- Science, Meriden, CT) with a Filtermate 96 harvester (Packard BioScience) and washed 3 times with cold 50 mM Tris-HCl, pH 7.4 buffer. Nonspecific binding was measured in the presence of 10 μM MPEP. The radioactivity on the filter was counted (3 min) on a Packard Top-count microplate scintillation counter with quenching correction after addition of 45 μl of microscint 40 (Canberra Packard S.A., Zurich, Switzerland) and shaking for 20 min.
For functional assays, [Ca2+]i measurements were performed as described previously by Porter et al. [Br. J. Pharmacol. 128:13-20 (1999)] on recombinant human mGlu 5a receptors in HEK-293 cells. The cells were dye loaded using Fluo 4- AM (obtainable by
FLUKA, 0.2μM final concentration). [Ca2+]i measurements were performed using a fluorometric imaging plate reader (FLIPR, Molecular Devices Corporation, La Jolla, CA, USA). Antagonist evaluation was performed following a 5 min preincubation with the test compounds followed by the addition of a submaximal addition of agonist. The inhibition (antagonists) curves were fitted with a four parameter logistic equation giving IC50, and Hill coefficient using an iterative non linear curve fitting software (Xcel fit).
For binding experiments the i values of the compounds tested are given. The Ki value is defined by the following formula:
Ki = IC50 / [l + L / Kd]
in which the IC50 values are those concentrations of the compounds tested which cause 50 % inhibition of the competing radioligand ([3H]MPEP). L is the concentration of radioligand used in the binding experiment and the Ka value of the radioligand is empiri- cally determined for each batch of membranes prepared.
Pharmaceutical Compounds are mGluR 5a receptor antagonists. The activities of Pharmaceutical Compounds as measured in the assay described above are in the range of Kj < 150 nM.
Activity data
Figure imgf000025_0001
Ki (mGluR5)
Activity specifically as anxiolytic agents maybe demonstrated in acordance with standard test methods, e.g. as described in the Vogel conflict drinking test [see e.g. review of Millan, Progress in Neurobiology 70:83-244 (2003)]:
The Vogel conflict drinking test is a procedure that has been widely used as a screening method for anxiolytics. In this procedure, the water intake of thirsty rats is measured under conditions where water intake is suppressed by electric shock. In our version of the test, rats are water-restricted for 23h during three consecutive days. One day after the first water restriction, they are allowed to freely drink for one hour in their home-cage. The second day, they are allowed to lick from a drinking spout in the operant box for 15 min, after which they are allowed to freely drink in their home cage for one hour. On the third - test - day, they are allowed to lick again from a drinking spout for 10 min, but now they receive a 0.5 mA electric stimulus for 0.5 sec every sec that they lick (counted as an interruption of an infrared beam in front of the spout). The electric stimulus suppresses the time that the animals spend drinking, and treatment with Pharmaceutical Compounds partially or completely reinstates normal drinking duration.
Pharmaceutical Compounds can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emul- sions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
Pharmaceutical Compounds can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, e.g., as such carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
As mentioned earlier, medicaments containing a Pharmaceutical Compound and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more Pharmaceutical Compound and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers. The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7- 1400 mg per day, preferably between 7 and 700 mg per day.
The following examples are provided to further elucidate the invention:
Preparation of the starting compounds
Example II- 1: 2-Me yl-4-(2-mefhyl-lH-imidazol-4-ylethynyl)-pyridine (II- 1)
Method Al:
Step 1: 2-Methyl- 1 - (2-trimethylsilanyl-ethoxymethyl) - lH-imidazole-4-carbaldehyde and
2-methyl-3-(2-trime1_hylsilanyl-efhoxymethyl)-3H-imidazole-4-carbaldehyde
A solution of 2-methyl- lH-imidazol-4-carbaldehyde (5.0 g, 45 mmol) in 125 mL dry DMF was added dropwise at 0°C to suspension of sodium hydride (1.98 g, 45 mmol) in dry DMF. The reaction mixture was stirred at RT for 2h. A solution of 2-(trimethylsilyl)eth- oxymethyl chloride (7.97 g, 45 mmol) in 50 mL dry THF was added dropwise at 0°C. The reaction mixture was stirred at RT overnight. Water (100 mL) was added carefully and the solvents were evaporated. The residue was taken up in 150 mL water and extracted three times with ethyl acetate (150 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product (mixture of 2 isomers, 12.5 g) was used without any further purification for the next step, MS: m/e = 241.2 (M+H+). Step 2: 4-Ethynyl-2-methyl-l-(2-frimemylsflanyl-etfroxymethyl)-lH-imidazole and 5- ethynyl-2-methyl-l-(2-trimethylsilanyl-ethoxymefhyl)-lH-imidazole (l-Diazo-2-oxo-propyl)-ρhosphonic acid dimethyl ester (10.4 g, 54 mmol) was dissolved in 150 mL methanol. Potassium carbonate (12.6 g, 90 mmol) was added. A solution of crude 2-methyl-l-(2-trimethylsilanyl-ethoxymethyl)-lH-imidazole-4-carbaldehyde and 2- methyl-3-(2-trimethylsflanyl-ethoxymethyl)-3H-imidazole-4-carbaldehyde (45 mmol) in 150 mmol methanol was added dropwise at RT. The reaction mixture was stirred at RT overnight. The solvent was evaporated. The residue was taken up in 150 mL water and ex- tracted three times with ethyl acetate ( 150 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by column chromatography on silica gel (cyclohexane / ethyl acetate 1:1) and the desired compound was obtained as a mixture of 2 isomers (8.36 g, 78%), MS: m/e = 237.0 (M+H+). Step 3: 2-Methyl-4- [2-methyl- 1- (2-trimethylsilanyl-ethoxymefhyl) - lH-imidazol-4-yl- ethynyl] -pyridine and 2-methyl-4- [2-me1^yl-3-(2-frimethylsilanyl-ethoxymethyl)-3H- imidazol-4-ylethynyl] -pyridine
4-Bromo-2-methyl-pyridine (1.92 g, 11.2 mmol) was dissolved in 50 mL dry THF and triethylamine (3.9 mL, 30 mmol) was added. This mixture was evacuated and backfilled with argon several times to remove oxygen from the solution. Triphenylphosphin (73 mg, 0.28 mmol) and bis(triphenylphosphin)palladium(II)chloride (327 mg, 0.47 mmol) were added and the reaction mixture was stirred at RT for 20 min. Copper(I)iodide (53 mg, 0.28 mmol) and a mixture of 4-ethynyl-2-methyl-l-(2-trimethylsilanyl-ethoxymethyl)-lH- imidazole and 5-etfrynyl-2-methyl-l-(2-trime1_hyl-sflanyl-ethoxymethyl)-lH-imidazole (2.2 g, 9.3 mmol) were added. The reaction mixture was then stirred at RT overnight. The solvent was evaporated. The residue was taken up in 50 mL water and extracted three times with ethyl acetate (70 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane / ethyl acetate 80:20 -> 0:100 gradient ) and the desired compound was obtained as a mixture of 2 isomers (2.86 g, 94%), MS: m/e = 327.2 (M ). Step 4: 2-Methyl-4-(2-methyl-lH-imidazol-4-ylethynyl -pyridine 2-Methyl-4-[2-me1±ιyl-l-(2-trimethylsflanyl-ethoxymethyl)-lH-imidazol-4-ylethynyl]- pyridine and 2-methyl-4- [2-methyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazol-4- ylethynyl] -pyridine (2.85 g, 8.7 mmol) were dissolved in 50 mL EtOH saturated with HCl. The reaction mixture was stirred at RT overnight. The solvent was evaporated. The residue was taken up in 50 mL water and adjusted to pH7 by addition of sodium hydroxide. The aqueous phase was extracted three times with ethyl acetate (70 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (methylene chloride / methanol 100:5 -> 85:15 gradient ) and the desired compound was obtained as an off-white foam (1.19 g, 69%), MS: m/e = 198.2 (M+H+).
Method A2:
Step 1: 4-Iodo-2-methyl-pyridine 4-Chloropicoline (10 g, 78 mmol), sodium iodide (17.8 g, 118 mmol) and hydroiodic acid (57%, 26 mL, 196 mmol) were heated in a sealed class tube at 140°C for 7 days. The reaction mixture was poured into ice water and neutralized by addition of sodium hydroxide. This mixture was extracted three times with dichloromethane (300 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The desired product was obtained as an off-white solid (14.7 g, 85%) and used without any further purification for the next step. Sje^^ 2-Methyl-4-trimethylsilanylethynyl-pyridine
4-Iodo-2-methyl-pyridine (9.5 g, 41.8 mmol) was dissolved in 150 mL dry THF and 18 mL triethyl amine. This mixture was evacuated and backfilled with argon several times to remove oxygen from the solution. Triphenylphosphine (341 mg, 1.25 mmol) andbis(tri- phenylphosphine)palladium(II) chloride (1.47 g, 2.09 mmol) were added and the reaction mixture was stirred at RT for lh. Copper(I)iodide (248 mg, 1.3 mmol) and trimethylsilyl- acetylen (6.39 g, 6.50 mmol) were added. The reaction mixture was stirred at RT overnight. The solvent was evaporated. The residue was taken up in 500 mL water and extracted three times with ethyl acetate (500 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane/ethyl acetate gradient 100:0 — 0:100). The desired product was obtained as a light brown liquid (8.18 g, 99%). Step 3: 2-Methyl-4-(2-methyl-lH-imidazol-4-ylethynyl -pyridine Solution 1: 2-Mefhyl-4-trimethylsilanylethynyl-pyridine (12 g, 74 mmol) and 5-iodo-2- methyl- lH-imidazole (13.24 g, 64 mmol, synthesis: Cliff and Pyne, Synthesis 681-682
(1994) were dissolved in 75 mL dry THF and 20 mL dry DMF. This mixture was evacuated and backfilled with argon several times to remove oxygen from the solution. Solution 2: Triphenylphosphine (223 mg, 0.85 mmol), bis (triphenylphosphine) -palladi- um(II) chloride (1.79 g, 2.55 mmol), copper(I)iodide (81 mg, 0.43 mmol) and triethyl amine (8.87 mL, 64 mmol) were dissolved in 75 mL dry THF. This mixture was also evacuated and backfilled with argon several times to remove oxygen from the solution. Solution 2 was heated to 40°C and solution 1 was added dropwise. The reaction mixture was heated to 60°C and tetrabutylammonium fluoride solution (1M in THF, 55 mL, 55 mmol) was added dropwise during 45 min. The reaction was than stirred at RT overnight. The solvent was evaporated. The residue was taken up in 200 mL water and extracted three times with ethyl acetate (200 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by chromatography on silica gel (methylene chloride/methanol 95:5) and recrystallized from a mixture of methylene chloride and ethyl acetate. The desired product was obtained as a light brown solid (7.44 g, 59%).
4-(2-Isopropyl-lH-imidazol-4-ylethynyl)-2-methyl-pyridine (II-2) [MS: m/e = 226.4 (M+H+)] was prepared in analogy to the method as described in example II-l, method A2, step 3 from 2-met yl-4-trimethylsilanylethynyl-pyridine and 5-iodo-2-isopropyl-lH- imidazole.
Example III- 1: 2-Chloro-5-methyl-pyrazine (III-l) 2-Hydroxy-5-methylpyrazine (0.984g, 8.94 mmol) was refluxed in 15 mL phosphoroxy- chloride for 1.5h. The reaction mixture was slowly poured into ice and adjusted to pH6 by addition of sodium carbonate. The mixture was extracted six times with ethyl acetate (50 mL each). The combined organic extracts were dried with sodium sulfate, filtered and eva- porated. The crude product was used without any further purification for the next step.
Example III-2: 4-Chloro-2-trifluoromethyl-pyrimidine (III-2)
This compound was prepared according to Inoue et al., J. Org. Chem. 26:4504 (1961).
Example III-3: 2-Bromo-6-fluoro-pyridine (III-3)
This compound was prepared according to WO 92/11,241.
Example IV- 1: 4-Emynyl-l-(4-fluoro-phenyl)-2-methyl-lH-imidazole (IV-1)
Step 1: l-(4-Fluoro-phenyl)-lH-imidazole-4-carboxylic acid ethyl ester 4-Fluoroaniline (20.0 g, 175 mmol) was mixted at RT with triethyl orthoformate (35.4 g, 233 mmol), ethylnitro acetate (28.5 g, 210 mmol) and 4 mL glacial acetic acid. The reaction mixture was refluxed with mechanical stirring for 2h. More triethyl orthoformate (200 mL) and glacial acetic acid (200 mL) were added. Iron powder (100 g, 1.79 mol) was added in 3 portions during 8h while maintaining the reaction mixture at reflux. Ethyl acetate (700 mL) was added and reflux was continued for another 2h. The reaction mixture was filtered through a dicalite speed plus pad and washed with 500 mL ethyl acetate. The solvents were evaporated and the crude product was used without any further purification for the next step.
Step 2: l-(4-Fluoro-phenyl)-lH-imidazole-4-carboxylic acid
Crude l-(4-fluoro-phenyl)-lH-imidazole-4-carboxylic acid ethyl ester (175 mmol) was dissolved in 450 mL dioxane and 450 mL 2N sodium hydroxide solution. The reaction mixture was refluxed for 2h. Charcoal (1 g, Norit SA II) was added and reflux was con- tinued for another 20 min. The mixture was filtered hot and washed with 50 mL 2N sodium hydroxide solution. The filtrate was treated with 550 mL 2N HCl and stirred at RT overnight. The solid material was filtered off and dried at 50°C and 15 mbar. The desired compound was obtained as an off-white solid (28 g, 78%), MS: m/e = 205.1 (M-H). Step 3: [l-(4-Fluoro-phenyl)-lH-imidazol-4-yl]-methanol l-(4-Fluoro-phenyl)-lH-imidazole-4-carboxylic acid (18 g, 87 mmol) was dissolved in 90 mL dry THF. Borane tetrahydrofuran complex (174 mL, 1M in THF, 174 mmol) was added dropwise. The reaction was refluxed for 2h and stirred at RT overnight. The reaction mixture was cooled to 0°C and 100 mL methanol were added dropwise. The solvents were evaporated. The residue was taken up in 100 mL 2N HCl and refluxed for 2h. The reaction mixture was then cooled to 0°C and 120 mL 2N sodium hydroxide solution were added dropwise. The solid material was filtered off and dried at 50°C and 15 mbar. The desired compound was obtained as a white solid (13 g, 78%), MS: m/e = 193.2 (M+H)+. Step 4: 4-(tert-Bu1yl-dimethyl-sπanyloxymethyl -l-(4-fluoro-phenyl)-lH-imidazole
[l-(4-Fluoro-phenyl)-lH-imidazol-4-yl]-mefhanol (13 g, 67.5 mmol) was dissolved 65 mL DMF. Imidazole (11 g, 162 mmol) and tert. butyldimethyl chlorosilane (12.2 g, 81 mmol) were added. The reaction mixture was stirred at 45°C overnight and poured into 500 mL water. The aqueous phase was extracted three times with ethyl acetate (200 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by column chromatography on silica gel (methylene chloride / methanol 98:2) and the desired compound was obtained as a light brown oil (20 g, 96%), MS: m/e = 291.2 (M-CH3), m/e = 249.1 (M-tert. butyl). Step 5: 4- (tert-Butyl-dimethyl-silanyloxymethyl)- 1- (4-fluoro-phenyl) -2-methyl- 1H- imidazole
4-(tert-Butyl-dimethyl-sflanyloxymefhyl)-l-(4-fluoro-phenyl)-lH-imidazole (18.2 g, 59.2 mmol) was dissolved in 600 mL dry THF and cooled to -78°C. n- Butyl lithium (55.5 mL, 1.6M in hexane, 88.8 mmol) was added dropwise. The reaction mixture was warmed up to -25°C, kept at -25°C for lOmin and then cooled again to -78°C. Iodomethane (7.4 mL, 11.9 mmol) was added dropwise. The reaction mixture was slowly warmed up to RT and stirred at RT overnight. The solvent was evaporated. The residue was taken up in 300 mL water and extracted three times with ethyl acetate (200 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by column chromatography on silica gel (cyclohexane / ethyl acetate 50:50 - 20:80 gradient) and the desired compound was obtained as an orange oil (14.7 g, 77%), MS: m/e = 321.1 (M+H+).
Step 6: [l-(4-Fluoro-phenyl)-2-methyl-lH-imidazol-4-yl1 -methanol 4- (tert-Butyl-dimethyl-silanyloxymethyl) - 1- (4-fluoro-phenyl) -2-methyl- lH-imidazole (14.7 g, 45.7 mmol) was dissolved in 200 mL THF. Tetrabutyl ammoniumfluoride (91 mL, IM in THF, 91 mmol) was added and the reaction mixture was stirred at RT overnight. The solvent was evaporated. The residue was taken up in 200 mL water and extracted three times with ethyl acetate (200 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was suspended in 150 mL ethyl acetate, filtered and dried. The desired compound was obtained as a white solid (7.16 g, 76%), MS: m/e = 207.1 (M+H+).
Step 7: 1 - (4-Fluoro-phenyl) -2-methyl- lH-imidazole-4-carbaldehyde [l-(4-Fluoro-phenyl)-2-methyl-lH-imidazol-4-yl] -methanol (7.16 g, 34.7 mmol) was dissolved in 2.3 L methylene chloride. Mangan (IV) oxid (26.8 g, 278 mmol) was added and the reaction mixture was stirred at RT for 3 days. The suspension was filtered through a dicalite speed plus pad and washed with 1 L methylene chloride. The solvents were eva- porated and the desired compound was obtained as a white solid (5.87 g, 83%), MS: m/e = 205.1 (M+H+).
Step 8: 4-Ethynyl- 1 - (4-fluoro -phenyl) -2-methyl- lH-imidazole
(l-Diazo-2-oxo-propyl)-phosphonic acid dimethyl ester (6.51 g, 33.9 mmol) was dissolved in 100 mL methanol. Potassium carbonate (7.81 g, 56.5 mmol) was added. A solution of l-(4-fluoro-phenyl)-2-methyl-lH-imidazole-4-carbaldehyde (5.77 g, 45 mmol) in 100 mmol methanol was added dropwise at RT. The reaction mixture was stirred at RT overnight. The solvent was evaporated. The residue was taken up in 150 mL water and extracted three times with ethyl acetate (150 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane / ethyl acetate 100:0 — > 0:100 gradient) and the desired compound was obtained as a white solid (3.81 g, 67%), MS: m/e = 200.1 (M+).
l-(3,4-DicUoro-phenyl)-4-ethynyl-2-methyl-lH-imidazole (IV-2) [MS: m/e = 252.1 (M+)] was prepared in accordance with the method of example IV- 1 from 3,4- dichloroaniline.
Example V-l: 2-Cyclopropyl-l-(4-fluoro-phenyl)-4-iodo-lH-imidazole (V-l)
Step 1: 2-Cyclopropyl-4,5-diiodo-lH-imidazole
2-Cyclopropyl-lH-imidazole (2500 mg, 23.12 mmol) was suspended in 46 ml 2N NaOH. A solution of iodine (11.74 g, 46.23 mmol) in 45 ml dichloromethane was added dropwise to the suspension within 15 min. The two-layer-mixture was stirred vigorously at RT over night. The aqueous layer was separated, neutralized with acetic acid and saturated
Na2S2O3-solution was added until the solution remained colorless. The suspension was stirred for 10 min, filtered and the solid was dried over night at 50°C under reduced pressure (<10 mbar). The desired compound was obtained as a light brown solid (3.51 g, 42%). Step 2: 2-Cyclopropyl-4-iodo~lH-imidazole
Na2SO3 (10.42 g, 82.65 mmol) was suspended in 40 ml water and 20 ml ethanol. 2-Cyclo- propyl-4,5-diiodo-lH-imidazole (3500 mg, 9.72 mmol) was added and the mixture was stirred at reflux for 16 hours. The reaction mixture was concentrated to 20 ml and then filtered. The solid was dried for 5 hours at 50°C under reduced pressure (<10 mbar) to get a light brown solid (1.50 g, 66%), MS: m/e = 235.1 (M+H+). Step_3: 2-Cyclopropyl- 1 - (4-fluoro-phenyl) -4-iodo- lH-imidazole
2-Cyclopropyl-4-iodo-lH-imidazole (500 mg, 2.14 mmol) was dissolved in 20 ml THF. 4- Fluorobenzene boronic acid (613 mg, 4.38 mmol) and [Cu(OH)TMEDA] 2C12 (347 mg, 0.75 mmol) were added. Oxygen was bubbled through the reaction mixture for 60 min and stirring was continued under an oxygen atmosphere at RT overnight. The reaction mixture was filtered through a dicalite speed plus pad and washed with.30 mL ethyl acetate. After drying the crude product was purified by flash chromatography on silica gel (heptane / ethyl acetate 90:10 -> 50:50 gradient) to get the desired compound as a white solid (320 mg, 46%), MS: m/e = 329.1 (M+H+).
Preparation of the compounds of formula I
Example 1 : 4- [ 1 - (4-Fluoro-phenyl) -2-methyl- lH-imidazol-4-ylethynyl] -2-methyl- pyridine (1)
Method A:
2-Methyl-4-(2-methyl-lH-imidazol-4-ylethynyl)-pyridine (II-l) (200 mg, 1.01 mmol) was dissolved in 10 mL dichloromethane. Powdered molecular sieves (3 A, 200 mg), 4-fluoro- benzene boronic acid (284 mg, 2.02 mmol) and [Cu(OH)TMEDA]2Cl2 (47 mg, 0.10 mmol) were added. Oxygen was bubbled through the reaction mixture for 5 min and stirring was continued at RT overnight. The reaction mixture was filtered through a dicalite speed plus pad and washed with 50 mL dichloromethane. The filtrate was washed with 50 ml water, dried with magnesium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (dichloromethane / methanol
100:0 - 85:15 gradient) and a mixture of 2 regioisomers was isolated. The desired compound was obtained by recrystaUization from diethylether as a white solid (151 mg, 51%), mp = 151°Q MS: m/e = 292.1 (M+H+).
Method B:
4-Iodo-2-methyl-pyridine (656 mg, 3.0 mmol) was dissolved in 10 mL dry THF and 10 mL piperidine. This mixture was evacuated and backfilled with argon several times to remove oxygen from the solution. Triphenylphosphine (20 mg, 0.07 mmol) and bis(triphenyl- phosphin)palladium(II) chloride (175 mg, 0.10 mmol) were added and the reaction mixture was stirred at RT for lh. Copper(I)iodide (14 mg, 0.07 mmol) and 4-ethynyl-l-(4- fluoro-phenyl)-2-methyl-lH-imidazole (IV-1) (500 mg, 2.5 mmol) were added. The reaction mixture was then refluxed for 3h. The solvent was evaporated. The residue was taken up in 30 mL water and extracted three times with ethyl acetate (50 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (dichloromethane / methanol 100:0 -» 90:10 gradient) and recrystaUization from diethylether and the desired product was obtained as a light yeUow solid (250 mg, 34%), mp = 151°C, MS: m/e = 292.1 (M+H+).
4-[l-(3,4-Dichloro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine hydrochloride (2) [MS: m/e = 341.9 (M+H+)] was prepared in analogy to the method as described in Example 1 Method B starting from l-(3,4-dichloro-phenyl)-4-ethynyl-2- methyl- IH-imidazole (IV-2) and 4-iodo-2-methyl-pyridine. For further purification the compound was precipitated as its HCl salt from an etheral solution.
Method C:
4-Iodo-2-methyl-lH-imidazole (200 mg, 1.0 mmol), 4-fluorophenylboronic acid (215 mg, 1.6 mmol), copper(II)acetate (210 mg, 1.2 mmol) and Et3N (0.16 ml, 1.2 mmol) were sus- pended in 10 ml THF and oxygen was bubbled through the reaction mixture for 40 min. The reaction mixture was stirred for 48 hours at RT and then filtrated over dicalit. The filtrate was concentrated and then purified by flash chromatography to yield l-(4-fluoro- phenyl)-4-iodo-2-methyl-lH-imidazole (120 mg, 0.40 mmol, 41 %).
A solution of l-(4-fluoro-phenyl)-4-iodo-2-methyl-lH-imidazole (5.0g, 17mmol) and 2- methyl-4-frimethylsilanylethynyl-pyidine (3.2 g, 17 mmol, prepared from 4-iodo-2-methyl pyridine and commerciaUy available ethynyl-trimethyl-sUane in a Sonogashira reaction) in 15ml THF was transferred to a mixture of triphenylphosphine (88 mg, 0.34 mmol), bis(tri- phenylphosphin)paUadium(II)chloride (705 mg, 1.0 mmol) and Et3N (3.5 ml. 25 mmol) in 80 ml THF. Copper(I)iodide (32 mg, 0.17 mmol) was added and the reaction mixture was heated under argon atmosphere to 40°C and a solution of tetrabutylammoniumfluoride (1 M in THF, 25.1 ml) was added over a period of 40 min. The reaction mixture was stirred for three hours at 40°C and then for 48 hours at RT. After aqueous work up and purification by chromatography over silica gel and crystaUization from ethylacetate and hexane the desired product was obtained as a light yeUow solid (2.8 g, 57%, mp = 151°C, MS: m/e = 292.1 (M+H+)).
The fallowing compounds were prepared in analogy to the method as described in the above Method A:
Figure imgf000034_0001
Figure imgf000035_0001
recrystaUization of the resulting regioisomers- mixture in ethyl acetate at RT
Example 2: 2- [2-Methyl-4-(2-meth.yl-pyridin-4-ylethynyl)-imidazol- 1-yl] -pyrimidine (8) 2-Methyl-4- (2-methyl- lH-imidazol-4-ylethynyl) -pyridine (II-l) (87 mg, 0.44 mmol) was dissolved in 3 mL dimethyl formamide. Potassium carbonate (122 mg, 0.88 mmol) and 2- chloro-pyrimidine (76 mg, 0.66 mmol) were added and the reaction mixture was refluxed overnight. The reaction mixture was poured into 60 mL water and extracted three times with ethyl acetate (50 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was treated with ethyl acetate (2mL) and diisopropyl ether (2mL). The solid was filtered off and washed with little diisoppropyl ether. The desired compound was as an off-white solid (49 mg, 50%), mp = 164-165°C, MS: m/e = 276.1 (M+H+).
The foUowing compounds were prepared in analogy to the method as described above:
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
* prepared according to Dunaiskis et al., Organic Preparations and Procedures
International 2:600-602 (1995)
** obtained as a mixture with 4-chloro-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)- imidazol- 1-yl] -pyrimidine and could be separated by chromatography
*** obtained as a mixture with 2-chloro-4-[2-methyl-4-(2-mefhyl-pyridin-4-ylethynyl)- imidazol- 1-yl] -pyrimidine and could be separated by chromatography
Example 3: 4-[2-Cyclopropyl-l-(4-fluoro-phenyl)-lH-imidazol-4-ylethynyl]-2-methyl- pyridine (54)
2-Cyclopropyl-l-(4-fluoro-phenyl)-4-iodo-lH-imidazole (V-l) (150 mg, 0.46 mmol) and 2-methyl-4-trimethylsUanylethynyl-pyridine (113 mg, 0.59 mmol) were dissolved in 4 mL dry THF. This mixture was evacuated and backfilled with argon several times to remove oxygen from the solution. In a second reaction vessel triphenylphosphine (4 mg, 0.01 mmol), bis(triphenylphosphine)-paUadium(II)chloride (16 mg, 0.02 mmol), copper(I)- iodide (1 mg, 0.01 mmol) and triethyl amine (0.10 mL, 0.69 mmol) were dissolved in 2 mL dry THF. This mixture was also evacuated and backfiUed with argon several times to remove oxygen from the solution. This mixture was heated to 40°C and the solution of 2- cyclopropyl- 1 - (4-fluoro-phenyl) -4-iodo- IH-imidazole and 2-methyl-4-trimefhylsUanyl- ethynyl-pyridine was added dropwise. The reaction mixture was heated to 60°C and tetra- butylammonium fluoride solution (IM in THF, 0.72 mL, 0.69 mmol) was added dropwise during 5 min. The reaction was than stirred at 40°C for 2 hours. The mixture was taken up in 20 mL water and extracted three times with ethyl acetate (20 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by chromatography on sflica gel (n-heptane/ethyl acetate 1:4) to ob- tain the desired title compound as a colorless solid (85 mg, 59%), MS: m/e = 318.1 (M+H+).
Example 4: 2-Methyl-6- [2-methyl-4- (2-memyl-pyridin-4-ylethynyl)-iιnidazol- 1-yl] - pyrazine (55), starting from a compound of formula I
2-CUoro-6-[2-methyl-4-(2-me1iιyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrazine (27)(300 mg, 0.968 mmol) was dissolved in 5 mL dry tetrahydrofuran. Dimethylzinc (1.2 mL, 2M in toluene) and tetrakis(triphenylphosphin)paUadium (23 mg, 0.02 mmol) were added. The reaction mixture was refluxed for 2h and poured into 50 mL sat. sodium bicarbonate solution. The mixture was extracted three times with ethyl acetate (50 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on sflica gel (dichloromethane / methanol 100:0 — 90:10 gradient) and the desired product was obtained as a light yeUow solid (240 mg, 85%), MS: m/e = 290.1 (M+H+).
The foUowing compounds were prepared in analogy to the method as described above:
Figure imgf000039_0001
Figure imgf000040_0001
* prepared according to De Lang and Brandsma, Synthetic Communications 28:225-232 (1998)
Example 5: 2-Butyl-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]- pyridine (65)
The title compound, MS: m/e = 331.3 (M+H+) was obtained as a by-product in the synthesis of 2-cyclopropyl-6- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1-yl] - pyridine (57) due to n-butyUithium impurities in the cyclopropylzinc chloride solution.
Example 6: 2-Bu1yl-5-[2-me yl-4-(2-methyl-pyridm-4-ylethynyl)-_unidazol-l-yl]- pyridine (66)
The title compound, MS: m/e = 331.1 (M+H+) was obtained as a by-product in the synthesis of2-cyclopropyl-5-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]- pyridine (59) due to n-butyUithium impurities in the cyclopropylzinc chloride solution.
Example 7: 2-Methoxy-6-[2-memyl-4-(2-metfryl-pyridin-4-yletiιynyl)-imidazol-l-yl]- pyrazine (67)
The title compound, MS: m/e = 306.5 (M+H+) was prepared by treatment of 100 mg 0.32 mmol) 2-chloro-6- [2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrazine (27) with 5 equiv. of sodium methoxide in 4 ml of methanol (3h, 55°C). The compound, after extraction with ethyl acetate / water, was purified by chromatography. Yield: 62 mg (0.203 mmol, 63%).
2-Methoxy-6-[2-methyl-4-(2-methyl-pyridin-4-ylefhynyl) -imidazol- 1-yl] -pyridine (68) [MS: m/e = 305.4 (M+H+)] was prepared in analogy to the method as described above from 6-fluoro-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyridine (33).
Example 8: 2-Methoxy-4- [2-methyl-4-(2-methyl-pyridin-4-ylethynyl) -imidazol- 1-yl] - pyridine (69)
FoUowing the Buchwald-protocol [Buchwald et al., Tetrahedron Lett. 40:2657 (1999)], a rigorously dried Schlenk tube was filled with argon and charged with copper(I) trifluoro- methanesulfonate benzene complex (101 mg, 0.2 mmol), phenanthroline (720 mg, 4.0 mmol), dibenzylideneacetone (47 mg, 0.2 mmol) and cesium carbonate (2.86 g, 8.8 mmol). 2-Methyl-4-(2-methyl-lH-imidazol-4-ylethynyl)-pyridine (II-l) (1.18 g, 6.0 mmol), o-xylene (1.6 ml) and 4-iodo-2-methoxyρyridine x HCl (1.1 g, 4.0 mmol) [Talik and Plazek, Rocz. Chem. 33:1343 (1959)] was added. The mixture was stirred at 110°C for 24 hr, cooled to RT and partitioned between CH C1 and saturated aqueous NH4C1 solution. The organic phase was concentrated and purified by chromatography on silica gel (dichloromethane / methanol 100:0 -» 97:3 gradient). The title compound was obtained as a tan semisolid material (44 mg, 4%). The free base was converted to the HCL salt, mp = 145-147°C (MeOH/Et2O), MS: m/e = 305.0 (M+H+).
Example 9: Dimethyl-{5- [2-memyl-4-(2-memyl-pyridm-4-ylemynyl)-iιnidazol-l-yl]- pyridin-3-yl}-amine (70)
3-Fluoro-5-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridine (48) (100 mg, 0.34 mmol) was dissolved in 5 mL dimethyl formamide. Potassium carbonate (189 mg, 1.38 mmol) and dimethylamine hydrochloride (42 mg, 0.52 mmol) were added and the reaction mixture was refluxed overnight. The reaction mixture was poured into 60 mL water and extracted three times with ethyl acetate (50 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on sflica gel (dichloromethane / methanol 100:0 -> 90:10 gradient) and the desired compound was obtained as an off-white solid (22 mg, 20%), MS: m/e = 318.2 (M+H+). The foUowing compounds were prepared in analogy to the method as described above:
Figure imgf000042_0001
Figure imgf000043_0001
Example 10: 2-(2-Mefhoxy-ethoxy)-6- [2-methyl-4-(2-methyl-pyridin-4-ylethynyl)- imidazol- 1-yl] -pyrazine (86)
The title compound, MS: m/e = 350.4 (M+H+) was prepared by treatment of 100 mg 0.32 mmol) 2-cUoro-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyrazine (27) with 3 equiv. of 2-methoxyethanol and 3 equiv. of sodium hydride in 5 ml of THF (lh, 50°C). The compound, after extraction with methylene chloride / water, was purified by chromatography. Yield: 45 mg (0.13 mmol, 40%).
2- (2-Methoxy-ethoxy) -6- [2-methyl-4- (2-methyl-pyridin-4-ylefhynyl)-imidazol- 1 -yl] - pyridine (87) [MS: m/e = 349.3 (M+H+)] was prepared in analogy to the method as described above from 6-fluoro-2-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl) -imidazol- 1- yl] -pyridine (33).
Example 11: 4-[l-(4-Fluoro-phenyl)-2,5-d4methyl-lH-imidazol-4-ylethynyl]-2-mefhyl- pyridine (88)
Diisopropylamine (0.260 mg, 2.6 mmol) was dissolved in 5 mL dry tetrahydrofurane, n- butyUithium (1.6 mL, 1.6 M in hexane, 2.6 mmol) were added at -78°C and the mixture was kept at -78°C for 10 min. 4-[l-(4-Fluoro-phenyl)-2-methyl-lH-imidazol-4-ylethyn- yl] -2-methyl-pyridine (1) (500 mg, 1.72 mmol) in 5 mL dry tetrahydrofurane was added at -78°C and stirring was continued for 45 min at this temperature. Methyl iodide (410 mg, 2.9 mmol) was added at -78°C and the reaction mixture was slowly warmed to RT. The reaction mixture was quenched by addition of 50 mL water and extracted three times with diethylether (100 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by column chromatography on silica gel (methylenchloride/methanol 9:1) and the desired compound was obtained as a white solid (325 mg, 62%), MS: m/e = 306.4 (M+H+).
3-(4-Fluoro-phenyl)-2-methyl-5-(2-methyl-pyridin-4-ylefhynyl)-3H-imidazole-4-carb- aldehyde (89) [MS: m/e = 320.4 (M+)] was prepared in analogy to the method as above from 4-[l-(4-Fluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl]-2-methyl-pyridine (l) and N,N-dimethyl-formamide.
Preparation of the pharmaceutical compositions:
Example I: Tablets
Tablets of the foUowing composition are produced in a conventional manner: mg/Tablet Active ingredient 100
Powdered, lactose 95 White corn starch 35
Polyvinylpyrrolidone 8
Na carboxymethylstarch 10
Magnesium stearate 2
Tablet weight 250
Example II: Tablets
Tablets of the foUowing composition are produced in a conventional manner: mg/Tablet Active ingredient 200
Powdered, lactose 100 White corn starch 64
Polyvinylpyrrolidone 12
Na carboxymethylstarch 20
Magnesium stearate 4
Tablet weight 400
Example III: Capsules
Capsules of the foUowing composition are produced: - 44 - mg/Capsule
Active ingredient 50
CrystaUine. lactose 60
MicrocrystaUine cellulose 34
Talc 5
Magnesium stearate 1
Capsule fill weight 150
The active ingredient having a suitable particle size, the crystaUine lactose and the microcrystaUine ceUulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed. The final mixture is filled into hard gelatine capsules of suitable size.

Claims

Claims
1. A compound which is a 4-[l-aryl-imidazol-4-ylemynyl]-2-aIkyl-pyridine derivative or a 4- [l-heteroaryl-imidazol-4-ylethynyl] -2-alkyl-pyridine derivative or a pharmaceuticaUy acceptable salt thereof.
2. The compound of claim 1 having the formula I
Figure imgf000046_0001
wherein
R1 is Q-C6alkyl;
R2 is C Cgalkyl or Q-Cπcycloalkyl; R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is unsubstituted or substituted by one, two or three substituents selected from halogen, CrCgalkyl, S-Q-Cgalkyl, Ci- Cgalkyl-halogen, Q-Cgalkoxy, halogen-Q-Cgalkoxy, Q-Cπcycloalkyl, C2- Qiheterocycloalkyl, CrCgalkylamino, di-Q-Cgalkylamino, Q-Cgalkoxyamino, (Q- Cgalkoxy)Q-Csalkylamino, C3-Q2cycloalkylamino, benzylamino and cyano; and R4 is hydrogen, C(O)H or CH2R5 wherein R5 is hydrogen, OH, Q-Cgalkyl or Q- Cι2cycloalkyl.
3. The compound according to claim 1 having the formula I*
Figure imgf000046_0002
wherein R1 signifies lower alkyl; R2 signifies lower alkyl; R3 signifies aryl or heteroaryl, optionaUy substituted, preferably by one, two or three substituents, selected from the group consisting of halogen, lower alkyl, lower alkyl- halo en or cyano; as well as to pharmaceutically acceptable salts thereof.
4. The compound of formula 1 according to claim 2 wherein R1 is methyl.
5. The compound of formula 1 according to claim 2 wherein R2 is Q-Cgalkyl.
6. The compound of formula 1 according to claim 2 wherein R3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halogen, Q-Cgalkyl, S-Q- Cgalkyl, Q-Cgalkyl-halogen, Q-Cgalkoxy, halogen-Ci-Cgalkoxy, C3-Cι2cycloaIkyl, C2- Qiheterocycloalkyl, Q-C6alkylamino, di-CrCgalkylamino, Q-Cgalkoxyamino, (Q- Cgalkoxy)Q-Cgalkylamino, Q-Cπcycloalkylamino, benzylamino and cyano.
7. The compound of formula 1 according to claim 2 wherein R3 is unsubstituted heteroaryl or heteroaryl substituted by one, two or three substituents selected from the group consisting of halogen, Q-Cgalkyl, S-Q-Cgalkyl, CrQalkyl-halogen, Q-Cgalkoxy, halogen- Q-Cgalkoxy, C3-Q2cycloalkyl, C2-Qιheterocycloalkyl, Q-Cgalkylamino, di-Q- Cgalkylamino, CrCgalkoxyamino, (Q-Cgalkoxy) CrCg kylamino, C3-Q2cycloalkylamino, benzylamino and cyano.
8. The compound of formula 1 according to claim 2 wherein R4 is hydrogen, C(O)H or CH3.
9. The compound according to claim 1 selected from
4- [ 1 -(4-fluoro-phenyl) -2-methyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine, 4- [ l-(3,4-dichloro-phenyl) -2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine hydrochloride, 4- [ 1 - (2,4-difluoro-phenyl) -2-methyl- lH-imidazol-4-ylethynyl] -2-methyl-pyridine, 4-[l-(3,4-difluoro-phenyl)-2-methyl-lH-imidazol-4-ylethynyl] -2-methyl-pyridine, 4-[2-methyl-4-(2-me1_hyl-pyridin-4-yletnynyl)-imidazol-l-yl]-benzonitrile, 3-[2-methyl-4-(2-memyl-pyridin-4-ylethynyl)-imidazol-l-yl]-benzonitrile, 2-methyl-4- [2-methyl- 1 - (3-trifluoromethyl-phenyl) - lH-imidazol-4-ylefhynyl] -pyridine, 2- [2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrimidine, 2-[2-methyl-4-(2-memyl-pyridin-4-ylethynyl)-imidazol-l-yl]-4-trifluoromefhyl- pyrimidine, 4-methoxy-2-[2-memyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrimidine, 2-cyclopropyl-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyrazine, 4-cUoro-2-[2-methyl-4-(2-methyl-pyriα n-4-ylemynyl)-imidazol-l-yl] -pyrimidine, 2-cyclopropyl-6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl] -pyridine, 2-methoxy-6- [2-methyl-4- (2-methyl-pyridin-4-ylethynyl) -imidazol- 1 -yl] -pyridine, dimethyl-{6-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-pyridin-2-yl}- amine, l-methyl-5-[2-methyl-4-(2-methyl-pyridin-4-ylethynyl)-imidazol-l-yl]-lH-indole, 4-[l-(4-fluoro-phenyl)-2,5-dimethyl-lH-imidazol-4-ylethynyl]-2-methyl-pyridine and 3-(4-fluoro-phenyl)-2-methyl-5-(2-me yl-pyridin-4-ylethynyl)-3H-imidazole-4- carb aldehyde.
10. A compound according to any one of claims 1 to 9 for use as therapeutic active substance, in particular as anxiolyticaUy active substance.
11. A process for the production of a compound of formula I
Figure imgf000048_0001
wherein R1 is Q-Cgalkyl;
R2 is CrCgalkyl or C3-Q2cycloalkyl;
R3 is unsubstituted aryl or aryl substituted by one, two or three substituents selected from halogen, CrCgalkyl, S-Q-Cgalkyl, Q-Cgalkyl-halogen, Q-Cgalkoxy, halogen-Q- Qalkoxy, Q-Cπcycloalkyl, Q-Qiheterocycloalkyl, CrCgalkylamino, di-Q-Cgalkyl- amino, CrCgalkoxyamino, (CrCgalkoxy)Q-Cgalkylamino, C3-Q2cycloalkylamino, benzylamino and cyano, unsubstituted heteroaryl or heteroaryl substituted by one, two or three substituents selected from the group consisting of halogen, Q-Cgalkyl, S- Q-Cgalkyl, Q-Cgalkyl-halogen, Q-Cgalkoxy, halogen-Cr alkoxy, Q-Q2cyclo alkyl, C2-Qιheterocycloalkyl, CrCgalkylamino, di-Ci-Cgalkylamino, Ci-Cgalkoxyamino, (CrCgalkoxy)Cι-Cgalkylamino) Q-Cπcycloalkylamino, benzylamino and cyano; and
R4 is hydrogen, C(O)H or CH2R5 wherein R5 is hydrogen, OH, Ci-Cgalkyl or C3- Q2cyclo alkyl; which process comprises reacting
(a) a compound of formula II
Figure imgf000049_0001
wherein R1, R2 and R4 have the meanings as defined above, with a compound of formula III
R3-Z (HI) wherein R3 has the meanings as defined above and Z is halogen or B(OH)2; or (b) a compound of formula IV
Figure imgf000049_0002
wherein R2, R3 and R4 have the meanings as defined above, with a compound of formula V
Figure imgf000049_0003
wherein R1 has the meanings as defined above and X is halogen; or (c) a compound of formula VI
R Vhal
(VI)
Ra wherein R2, R3 and R4 have the meanings as defined above and hal is halogen, with a compound of formula VII
Figure imgf000049_0004
wherein R1 has the meaning as defined above.
12. A pharmaceutical composition, in particular for use as an anxiolytic comprising a compound according to any one of claims 1 to 9 and a therapeuticaUy inert carrier.
13. The use of a compound according to any one of claims 1 to 9 for the manufacture of a medicament for the treatment and prevention of mGluR5 receptor mediated disorders, in particular anxiety.
14. A method for the treatment or prevention of a disease or condition in which metabotropic glutamate receptor subtype 5 activation plays a role or is implicated comprising administering to a mammal in need thereof a therapeuticaUy effective amount of a com- pound according to claim 1.
15. The invention as hereinbefore described.
PCT/EP2004/002276 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives WO2004080998A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DK04717578T DK1606277T3 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives
AU2004220382A AU2004220382B2 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives
EP04717578A EP1606277B8 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives
BRPI0408093-9A BRPI0408093A (en) 2003-03-10 2004-03-05 imidazol-4-yl-ethynyl-pyridine derivatives.
ES04717578T ES2305739T3 (en) 2003-03-10 2004-03-05 DERIVATIVES OF IMIDAZOL-4-IL-ETINIL-PIRIDINA.
PL04717578T PL1606277T3 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives
SI200430735T SI1606277T1 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives
NZ541643A NZ541643A (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives
JP2006504558A JP4404896B2 (en) 2003-03-10 2004-03-05 Imidazole-4-yl-ethynyl-pyridine derivatives
DE602004013746T DE602004013746D1 (en) 2003-03-10 2004-03-05 Imidazole-4-YL-ETHYNYL-PYRIDINE DERIVATIVES
CA002516682A CA2516682C (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives
MXPA05009524A MXPA05009524A (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives.
IL170129A IL170129A (en) 2003-03-10 2005-08-04 Imidazol-4-yl-ethynyl-pyridine derivatives, pharmaceutical compositions comprising the same, process for their production and use thereof in the manufacture of medicaments
HR20050774A HRP20050774A2 (en) 2003-03-10 2005-09-05 Imidazol-4-yl-ethylnyl-pyridine derivatives
NO20054136A NO20054136L (en) 2003-03-10 2005-09-06 Imidazol-4-yl-ethynyl-pyridine derivatives
HK06109889A HK1089443A1 (en) 2003-03-10 2006-09-06 Imidazol-4-yl-ethynyl-pyridine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004952.2 2003-03-10
EP03004952 2003-03-10

Publications (1)

Publication Number Publication Date
WO2004080998A1 true WO2004080998A1 (en) 2004-09-23

Family

ID=32981724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002276 WO2004080998A1 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives

Country Status (31)

Country Link
US (1) US7153874B2 (en)
EP (1) EP1606277B8 (en)
JP (1) JP4404896B2 (en)
KR (1) KR100742019B1 (en)
CN (1) CN100358889C (en)
AR (1) AR043501A1 (en)
AT (1) ATE395345T1 (en)
AU (1) AU2004220382B2 (en)
BR (1) BRPI0408093A (en)
CA (1) CA2516682C (en)
CL (1) CL2004000449A1 (en)
CO (1) CO5601027A2 (en)
DE (1) DE602004013746D1 (en)
DK (1) DK1606277T3 (en)
ES (1) ES2305739T3 (en)
HK (1) HK1089443A1 (en)
HR (1) HRP20050774A2 (en)
IL (1) IL170129A (en)
MX (1) MXPA05009524A (en)
MY (1) MY135491A (en)
NO (1) NO20054136L (en)
NZ (1) NZ541643A (en)
PA (1) PA8597301A1 (en)
PE (1) PE20041061A1 (en)
PL (1) PL1606277T3 (en)
PT (1) PT1606277E (en)
RU (1) RU2342383C2 (en)
SI (1) SI1606277T1 (en)
TW (1) TWI292318B (en)
WO (1) WO2004080998A1 (en)
ZA (1) ZA200506834B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118568A1 (en) * 2004-06-01 2005-12-15 F. Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
DE102006011574A1 (en) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituted imidazo [2,1-b] thiazole compounds and their use for the preparation of medicaments
EA011722B1 (en) * 2004-06-01 2009-04-28 Ф.Хоффманн-Ля Рош Аг Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
WO2011006910A1 (en) * 2009-07-17 2011-01-20 F. Hoffmann-La Roche Ag Imidazole derivatives as mglur5 antagonists
WO2011073172A1 (en) * 2009-12-17 2011-06-23 F. Hoffmann-La Roche Ag Ethynyl derivatives
US8063076B2 (en) 2006-12-21 2011-11-22 Hoffmann-La Roche Inc. Solid forms of 2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
US8957213B2 (en) 2011-04-26 2015-02-17 Hoffman-La Roche Inc. Ethynyl compounds
US9682959B2 (en) 2013-07-08 2017-06-20 Hoffmann-La Roche Inc. Ethynyl derivatives
WO2018130437A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2018130443A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
EP3400220A4 (en) * 2016-01-05 2019-06-05 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
WO2022207479A1 (en) 2021-03-27 2022-10-06 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
WO2023089049A2 (en) 2021-11-19 2023-05-25 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP4069685A1 (en) * 2019-12-02 2022-10-12 F. Hoffmann-La Roche AG Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors
CN111416154B (en) * 2020-05-22 2021-08-06 松山湖材料实验室 Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304910A1 (en) * 1987-08-28 1989-03-01 G.D. Searle & Co. Biarylalkylimidazole derivatives as antidepressants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (en) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazole compounds and their manufacturing process
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4711962A (en) 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
HU217958B (en) 1989-06-30 2000-05-28 E. I. Du Pont De Nemours And Co. Substituted imidazole derivatives, pharmaceutical compositions containing them and process for producing them
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
BR9811933A (en) 1997-08-14 2000-09-05 Hoffmann La Roche Vinyl heterocyclic ethers against neurological disorders
EP1214303A1 (en) 1999-08-31 2002-06-19 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
EP1349839B8 (en) 2000-12-04 2005-06-22 F. Hoffmann-La Roche Ag Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
CA2470612A1 (en) * 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304910A1 (en) * 1987-08-28 1989-03-01 G.D. Searle & Co. Biarylalkylimidazole derivatives as antidepressants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARENA F ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS IN REACTIVATORS OF ORGANOPHOSPHORUS-INHIBITED ACETYLCHOLINESTERASE.10. HYDROXYIMINOMETHYLARYLETHENYLPYRIDINE METHIODIDES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 18, no. 11, 1975, pages 1147 - 1150, XP001005697, ISSN: 0022-2623 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293916B2 (en) 2004-06-01 2012-10-23 Hoffmann-La Roche Inc. Diazole derivatives
EA011722B1 (en) * 2004-06-01 2009-04-28 Ф.Хоффманн-Ля Рош Аг Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
CN1960984B (en) * 2004-06-01 2010-05-12 弗·哈夫曼-拉罗切有限公司 Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
WO2005118568A1 (en) * 2004-06-01 2005-12-15 F. Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
DE102006011574A1 (en) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituted imidazo [2,1-b] thiazole compounds and their use for the preparation of medicaments
JP2009529508A (en) * 2006-03-10 2009-08-20 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Substituted imidazo [2,1-b] thiazole compounds and their use in the manufacture of a medicament
US7893069B2 (en) 2006-03-10 2011-02-22 Gruenenthal Gmbh Substituted imidazo[2,1-b]thiazole compounds and uses thereof
US8329912B2 (en) 2006-12-21 2012-12-11 Hoffmann-La Roche Inc. Solid forms of 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
US8063076B2 (en) 2006-12-21 2011-11-22 Hoffmann-La Roche Inc. Solid forms of 2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
WO2011006910A1 (en) * 2009-07-17 2011-01-20 F. Hoffmann-La Roche Ag Imidazole derivatives as mglur5 antagonists
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
AU2010272585B2 (en) * 2009-07-17 2013-11-07 F. Hoffmann-La Roche Ag Imidazole derivatives as mGluR5 antagonists
KR101431347B1 (en) 2009-07-17 2014-08-19 에프. 호프만-라 로슈 아게 Imidazole derivatives as mglur5 antagonists
WO2011073172A1 (en) * 2009-12-17 2011-06-23 F. Hoffmann-La Roche Ag Ethynyl derivatives
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8957213B2 (en) 2011-04-26 2015-02-17 Hoffman-La Roche Inc. Ethynyl compounds
US9682959B2 (en) 2013-07-08 2017-06-20 Hoffmann-La Roche Inc. Ethynyl derivatives
EP3400220A4 (en) * 2016-01-05 2019-06-05 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
US10941132B2 (en) 2016-01-05 2021-03-09 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
WO2018130437A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2018130443A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2022207479A1 (en) 2021-03-27 2022-10-06 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
WO2023089049A2 (en) 2021-11-19 2023-05-25 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives

Also Published As

Publication number Publication date
US20040229917A1 (en) 2004-11-18
DE602004013746D1 (en) 2008-06-26
AU2004220382B2 (en) 2007-08-02
RU2005131165A (en) 2007-04-20
AR043501A1 (en) 2005-08-03
TWI292318B (en) 2008-01-11
KR20050109074A (en) 2005-11-17
CA2516682C (en) 2010-02-02
RU2342383C2 (en) 2008-12-27
CN1759111A (en) 2006-04-12
JP2006519802A (en) 2006-08-31
EP1606277B1 (en) 2008-05-14
JP4404896B2 (en) 2010-01-27
PE20041061A1 (en) 2005-01-22
BRPI0408093A (en) 2006-02-14
IL170129A (en) 2013-02-28
NO20054136L (en) 2005-09-26
HK1089443A1 (en) 2006-12-01
ATE395345T1 (en) 2008-05-15
EP1606277A1 (en) 2005-12-21
US7153874B2 (en) 2006-12-26
MXPA05009524A (en) 2005-10-18
CL2004000449A1 (en) 2005-01-07
PL1606277T3 (en) 2008-10-31
DK1606277T3 (en) 2008-08-18
MY135491A (en) 2008-04-30
EP1606277B8 (en) 2008-10-15
TW200423935A (en) 2004-11-16
PT1606277E (en) 2008-07-08
ZA200506834B (en) 2006-05-31
NO20054136D0 (en) 2005-09-06
CN100358889C (en) 2008-01-02
AU2004220382A1 (en) 2004-09-23
CA2516682A1 (en) 2004-09-23
ES2305739T3 (en) 2008-11-01
PA8597301A1 (en) 2004-09-16
NZ541643A (en) 2008-03-28
SI1606277T1 (en) 2008-08-31
HRP20050774A2 (en) 2006-09-30
KR100742019B1 (en) 2007-07-23
CO5601027A2 (en) 2006-01-31

Similar Documents

Publication Publication Date Title
EP1606277B1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
US8481548B2 (en) Imidazole derivatives
CA2568725C (en) Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
IL172080A (en) Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists
IL179524A (en) Pyridin- 4 - yl - ethynyl - imidazoles, process for their preparation, medicaments comprising them and use thereof in the manufacture of medicaments for the treatment and prevention of mglu5 receptor mediated disorders
CA2531210C (en) Imidazole derivatives and their use in the treatment of mglur5 receptor mediated disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2005-501615

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 541643

Country of ref document: NZ

Ref document number: 170129

Country of ref document: IL

Ref document number: 2004717578

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004220382

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2516682

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005/06834

Country of ref document: ZA

Ref document number: 05085015

Country of ref document: CO

Ref document number: 200506834

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2004220382

Country of ref document: AU

Date of ref document: 20040305

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004220382

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P20050774A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009524

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057016753

Country of ref document: KR

Ref document number: 2186/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20048065725

Country of ref document: CN

Ref document number: 2006504558

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005131165

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020057016753

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004717578

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408093

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2004220382

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2004717578

Country of ref document: EP